# EDGAR Filing Document

**Accession Number:** 0001918617
**File Stem:** 0001918617-23-000001
**Filing Date:** 2023-1
**Character Count:** 211741
**Document Hash:** 03f47bd526e5277d1a14050ad5060c7f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001918617-23-000001.hdr.sgml**: 20230127

**ACCESSION NUMBER**: 0001918617-23-000001

**CONFORMED SUBMISSION TYPE**: C

**PUBLIC DOCUMENT COUNT**: 12

**FILED AS OF DATE**: 20230127

**DATE AS OF CHANGE**: 20230127

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** MedFire Innovations Inc.
- **CENTRAL INDEX KEY:** 0001918617
- **IRS NUMBER:** 813017806
- **STATE OF INCORPORATION:** CA
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** C
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 020-31686
- **FILM NUMBER:** 23559623

**BUSINESS ADDRESS:**
- **STREET 1:** 2425 CAMINO DEL RIO SOUTH, STE. 125
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92108
- **BUSINESS PHONE:** (888) 560-1140

**MAIL ADDRESS:**
- **STREET 1:** 2425 CAMINO DEL RIO SOUTH, STE. 125
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92108

### Attached PDF Documents

**Attachment 1:** `medformc.pdf`

# UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM C UNDER THE SECURITIES ACT OF 1933

(Mark one.)

☑ Form C: Offering Statement
☐ Form C-U: Progress Update
☐ Form C/A: Amendment to Offering Statement
☐ Check box if Amendment is material and investors must reconfirm within five business days.
☐ Form C-AR: Annual Report
☐ Form C-AR/A: Amendment to Annual Report
☐ Form C-TR: Termination of Reporting

*Name of issuer*

Medfire Innovations Inc.

*Legal status of issuer*

*Form*

General Stock Corporation

*Jurisdiction of Incorporation/Organization*

California

*Date of organization*

June 22, 2016

1

# *Physical address of issuer*

2425 Camino Del Rio South, Suite 125, San Diego, CA 92108

# *Website of issuer*

www.medfire.com

# *Name of intermediary through which the offering will be conducted*

MiTec, PBC (under trade name Crowdfund Main Street)

# *CIK number of intermediary*

0001690300

# *SEC file number of intermediary*

007-00133

# *CRD number, if applicable, of intermediary*

292759

*Amount of compensation to be paid to the intermediary, whether as a dollar amount or a percentage of the offering amount, or a good faith estimate if the exact amount is not available at the time of the filing, for conducting the offering, including the amount of referral and any other fees associated with the offering*

6% of proceeds distributed to the issuer plus third-party background checks and escrow fees.

*Any other direct or indirect interest in the issuer held by the intermediary, or any arrangement for the intermediary to acquire such an interest*

None

2

*Type of security offered*

Equity

*Price (or method for determining price)*

Face value

*Target offering amount*

$50,000

*Oversubscriptions accepted:*

☑ Yes

☐ No

*Oversubscriptions will be allocated:*

☐ Pro-rata basis

☑ First-come, first-served basis

☐ Other:

*Maximum offering amount (if different from target offering amount)*

$1,000,000

*Deadline to reach the target offering amount*

April 30, 2023

**NOTE:** If the sum of the investment commitments does not equal or exceed the target offering amount at the offering deadline, no securities will be sold in the offering, investment commitments will be cancelled and committed funds will be returned.

5

# *Current number of employees*

Two

*Financial summary*

|  | Most recent fiscal year end (2021) | Prior fiscal year end (2020) |
| --- | --- | --- |
| Total Assets | $99,984 | $96,275 |
| Cash and Cash Equivalents | $27,408 | $32,059 |
| Accounts Receivable | $0 | $0 |
| Short-term Debt | $32,998 | $31,443 |
| Long-term Debt | $101,762 | $94,289 |
| Revenues/Sales | $21,762 | $187,068 |
| Cost of Goods Sold | $17,573 | $102,687 |
| Taxes Paid | $2,268 | $800 |
| Net Income (Loss) | $(87,819) | $(3,195) |

4

# *The jurisdictions in which the issuer intends to offer the securities*

Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Puerto Rico, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, Wyoming

5

Pursuant to the requirements of Sections 4(a)(6) and 4A of the Securities Act of 1933 and Regulation Crowdfunding (§ 227.100 et seq.), the issuer certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form C and has duly caused this Form to be signed on its behalf by the duly authorized undersigned.

ISSUER

MEDFIRE INNOVATIONS INC.

Signature: Gregory Christmas

Title: Founder / President / Board Member

Pursuant to the requirements of Sections 4(a)(6) and 4A of the Securities Act of 1933 and Regulation Crowdfunding (§ 227.100 et seq.), this Form C has been signed by the following persons in the capacities and on the dates indicated.

Signature: Gregory Christmas

Title: Founder / President / Board Member

Date: 1/24/2023

6

# Form C
Offering Statement
of

MEDFIRE INNOVATIONS, INC.

“MedFire,” the “issuer,” the “company,” “we,” “our,” “us”)

# Stock Offering
(“Equity”)

*Forward-Looking Statement Disclosure*

This Form C, including any Exhibits referred to in this offering statement, and the intermediary’s website contain forward-looking statements and are subject to risks and uncertainties. All statements other than statements of historical fact or relating to present facts or current conditions included in this Form C are forward-looking statements. Forward-looking statements give the company’s current reasonable expectations and projections relating to its financial condition, results of operations, plans, objectives, future performance and business. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These statements may include words such as “will,” “anticipate,” “estimate,” “expect,” “project,” “plan,” “intend,” “believe,” “may,” “should,” “can have,” “likely,” and other words and terms of similar meaning in connection with any discussion of the timing or nature of future operating or financial performance or other events.

The forward-looking statements contained in this Form C, including any Exhibits referred to in this offering statement, and on the intermediary’s website, are based on reasonable assumptions the company has made in light of its industry experience, perceptions of historical trends, current conditions, expected future developments, and other factors it believes are appropriate under the circumstances. As you read and consider this Form C, including the Exhibits referred to in this offering statement, and the information on the intermediary’s website, you should understand that these statements are not guarantees of performance, results, or other events, all of which involve risks, uncertainties (many of which are beyond the company’s control), and assumptions. Although the company believes that these forward-looking statements are based on reasonable assumptions, you should be aware that many factors could affect its actual operations, operating or financial performance, and other actual future events, and cause such operations, performance, and events to differ materially from the operations, performance, and events anticipated in the forward-looking statements. Should one or more of these risks or uncertainties materialize, or should any of these assumptions prove incorrect or change, the company’s actual operations, operating or financial performance, or other actual future events may vary in material respects from the performance projected in these forward-looking statements.

7

Any forward-looking statement made by the company in this Form C, including any Exhibits referred to in this offering statement, or on the intermediary’s website speaks only as of the date of this Form C. Factors or events that could cause our actual operations, our operating or financial performance, or other future events to differ may emerge from time to time, and it is not possible for the company to predict all of them. The company undertakes no obligation to update any forward-looking statement, or other statement in this Form C, including any Exhibits referred to in this offering statement, or on the intermediary’s website, whether as a result of new information, future developments or otherwise, including decisions made at the company’s option, except as may be required by law.

#### *About this Form C*

You should rely only on the information contained in this Form C (including the Exhibits referred to in this offering statement). You should assume that information contained in this Form C (including the Exhibits referred to in this offering statement) is accurate only as of the date of this Form C, regardless of the time of delivery of this Form C or of any sale of securities. Our business, financial condition, results of operations, and prospects may have changed since that date.

This Form C (including the Exhibits referred to in this offering statement) does not purport to contain all of the information that may be required to evaluate this offering and any recipient of this Form C should conduct its own independent analysis. The statements of the company contained in this Form C are based on information believed to be reliable. No warranty can be made as to the accuracy of such information or that circumstances have not changed since the date of this Form C. The company does not expect to update or otherwise revise this Form C or other materials supplied herewith. The delivery of this Form C at any time does not imply that the information contained in this Form C is correct as of any time subsequent to the date of this Form C. This Form C is submitted in connection with this offering described herein and may not be reproduced or used for any other purpose.

Pursuant to Rule 201 of Regulation Crowdfunding (§ 227.201), an issuer offering or selling securities in reliance on section 4(a)(6) of the Securities Act of 1933, as amended (the “Securities Act”) must disclose the following information.

**(a) The name, legal status (including its form of organization, jurisdiction in which it is organized and date of organization), physical address and Web site of the issuer.**

8

| Name | Form of Organization | Jurisdiction of Organization | Date of organization | Physical address | Website |
| --- | --- | --- | --- | --- | --- |
| MedFire Innovations, Inc. | General Stock Corporation | California | June 22, 2016 | 2425 Camino Del Rio South, Suite 125, San Diego, CA 92108 | www.medfire.com |

**(b) The names of the directors and officers (and any persons occupying a similar status or performing a similar function) of the issuer, all positions and offices with the issuer held by such persons, the period of time in which such persons served in the position or office and their business experience during the past three years, including:**

**(1) Each person's principal occupation and employment, including whether any officer is employed by another employer; and**

**(2) The name and principal business of any corporation or other organization in which such occupation and employment took place.**

Directors and officers and their positions with the issuer:

| Name | Position(s) at issuer | Time period position(s) at the issuer have been held |
| --- | --- | --- |
| Gregory Christmas | Chairman of the Board and Company President | Chairman of the Board member from 2016 - present. Company President 2016 - present |
| Kenneth Conteen | Board member | Board member from 2019 - present |
| Staci Mehl | Board member | Board member from 2019 - present |
| Ilka De Leon | Board member | Board member from 2020 - present. |

9

Principal occupation and employment of directors and officers over the past three years:

| Name | Employer | Employer's principal business | Title or Role | Responsibilities | Dates of service |
| --- | --- | --- | --- | --- | --- |
| Gregory Christmas | MedFire Innovations Inc. | Product and service development | Chairman of the Board, and President of Company | Oversee the day-to-day operations, development of products and services, company finance and capital raise. | 2016 - present |
| Kenneth Conteen | American Airlines | Air Service | Senior Data Architect | Management of cloud-based software development | 2009 - present |
| Staci Mehl | Consultant | Medical Device and Equipment Consultant | Independent Consultant | Provides sales consultant services for medical products and devices | 2016 - present |
| Ilka De Leon | MedFire Innovations, Inc. and Eevolve, Inc. | Products and service development, and independent consultant. | Executive Vice President | Provide consultant work for product and device development and sales | 2020 - present. |

**(c) The name of each person, as of the most recent practicable date but no earlier than 120 days prior to the date this offering statement is filed, who is a beneficial owner of 20 percent or more of the issuer's outstanding voting equity securities, calculated on the basis of voting power.**

10

| Name | Ownership percentage |
| --- | --- |
| Gregory Christmas | 76.63% of common shares |

# **(d) A description of the business of the issuer and the anticipated business plan of the issuer.**

MedFire Innovations is comprised of various divisions focused on developing products, devices, and services for our company and for others. The three distinct divisions of MedFire are all tied together by a commitment to *Help Those Who Are In The Business Of Helping Others*. MedFire has cultivated a vast network of creative and innovative experts to help develop great ideas from concept to tactical reality. We have created a Culture of Innovation by sharing ideas and concepts within this network of biomedical, mechanical, and electrical engineers; manufacturers; packaging experts; technical and regulatory specialists; sales and marketing professionals; and other key experts, all with one goal in mind - To Bring Innovations To Life.

Our primary company and lead division, MedFire Innovations, is focused on the development and manufacturing of products and devices for those in the fields of Medicine and Science, Public Safety and Allied Health, Start-up Companies and Entrepreneurs, and MedTech Business in need of additional resources. This division is where Doctors, Nurses, Scientists, Public Safety Professionals, Veterinarians, and the like, come to move their ideas from the drafting table to the operating table, and from the scratch paper to the field. This division provides a diverse array of services in support of the creation of products and services aimed to serve those in the medical, science, and public safety communities.

In addition to our founding and primary company division, MedFire offers two additional divisions serving those who work in the fields of Medicine, Nursing, Science, Veterinary Medicine, and Public Safety: MedFire Jobs and MedFire Expo. Both divisions provide services to individuals and entities who work primarily in our target fields by providing advertising and marketing of products and services targeting these specialized audiences.

MedFire Jobs is a niche job search platform specifically designed to serve organizations and hires in the fields of Medicine, Science, Nursing, Fire and EMS, Law Enforcement, Veterinary Medicine, and other Public Safety professions. Job seekers can explore posted job or career opportunities while MedFire Jobs’ robust hiring platform equips employers with thorough job posting services and secure video interview capabilities to assist with recruiting. Featured company and featured advertisement services further allow an employer to improve visibility of their job placements, if they wish to do so. Designed to specifically serve the needs of these industry sectors, MedFire Jobs provides a convenient, results-driven user experience for both employers and job seekers.

MedFire Expo is an online marketplace, a dedicated environment in which users can form and nurture the relationships that matter for their business success. The Expo will provide a business with a place to connect sales with sales prospects, identify new markets, and grow a brand through strategic alignment and networking. Members of the Expo will also enjoy a platform to shop for products and services that cater to those in the healthcare, medical, emergency services, and related

11

fields. This platform will be an exciting place for those to come and experience. This division of MedFire Innovations will provide a variety of services to our customers and end-users through various means, including but not limited to: sales and marketing, eCommerce, a visual expo, and enhanced customized product experiences.

Through its three divisions of MedFire Innovations, MedFire Jobs, and MedFire Expo, parent company MedFire Innovations takes a comprehensive approach to delivering innovative products and services, career support, and extensive networking with a singular goal of improving the ways those in the health/medical, emergency services and public care spheres are able to serve and use their expertise, whether in traditional roles or through ideation and invention that moves their specialties forward in new ways, for the good of all.

MedFire plans to continue to develop, manufacture, and sell products and services it has created under MedFire Innovations or via its collaboratives with select organizations, groups, or other individuals. We also intend to be a profitable company and will try to achieve growth year over year for our company employees and shareholders by expanding future operations while continuously growing our primary target markets. As Company growth and revenues enable such expansion, MedFire also intends to develop a philanthropic arm of the Company. The following areas are on our intended roadmap for expansion: MedFire Labs and the MedFire Educational Center.

We envision future expansion of our company by expanding in various areas, while at the same time, staying focused on our primary target markets. As MedFire grows and increases revenues allowing for future expansion, MedFire intends to use some future proceeds to expand by developing both for profit divisions and increase our philanthropy. The following areas will be our intended roadmap for expansion: MedFire Labs, and the MedFire Educational Center.

The Company intends to move forward soon with an additional division - MedFire Labs. This division is being created to facilitate the need to provide supplements and other products to our target audiences, including resources for fitness and health. We will provide end-user customers with premium, lab-tested, supplements formulated specifically for the high-performance our customers need to stay in top physical condition, both physically and mentally. MedFire Labs supplements will be made in the USA in FDA Registered facilities. This division will provide our customers with top resources boasting the latest information on these topics.

MedFire envisions a world of possibility. We may use some of our future profits to develop and maintain a place for our younger generation to be creative, learn, develop, and ultimately, feel safe. The MedFire Center(s) can be this place. These centers would provide free, hands-on learning, lectures on life and business, creative collectives, and a safe place to spend time. The Centers could allow younger people opportunities for mentorship or other collaborations with professionals who have already established themselves in the sciences, medicine, nursing, fire and rescue, and in product development for these industries. The goal of MedFire Educational Center is to create a Center that achieves immediate and lasting change in the lives of those who attend, instilling confidence, supporting success, promoting kindness, and empowering a future ability to *pay it forward*.

MedFire was founded to impact communities through innovation. To further this impact and pay our success forward, we plan to use some of our profits to help those who want to help other as

12

defined in our Vision and Mission. We intend to use up to 10% of our annual net profits, as determined by our Board of Directors to be in the best interests of the Company, to provide funding to innovators with new ideas that would improve the safety and capabilities of those who work directly in the medical, public safety, and emergency service professions.

Please see **Exhibit A**, our Pitch Deck, for a description of our business and business plan and **Exhibit B**, our MedFire Executive Team. For further information, please also see **Exhibit C**, a description of our intended use of proceeds, **Exhibit D**, our Audited Financials, **Exhibit E**, our possible future operations, **Exhibit F**, the form of our Subscription Agreement, and **Exhibit G**, our Crowdfunding Page, **Exhibit H**, our Amended Articles of Incorporation, **Exhibit I**, Offering Video Transcript, and **Exhibit J**, Jobs & Expo Video Transcript.

### (e) The current number of employees of the issuer.

Two

### (f) A discussion of the material factors that make an investment in the issuer speculative or risky.

In deciding whether to participate in this Offering, prospective investors should carefully consider the risks related to purchasing and holding the Shares, including the risks described below. In addition to the risks described below, businesses are often subject to risks not foreseen or fully appreciated by management. In reviewing this Offering Memorandum, potential investors should keep in mind other possible risks that could be important.

These Securities have not been recommended or approved by any federal or state securities commission or regulatory authority. Furthermore, these authorities have not passed upon the accuracy or adequacy of this document. The SEC does not pass upon the merits of any Securities offered or the terms of the Offering, nor does it pass upon the accuracy or completeness of any offering document or literature. These Securities are offered under an exemption from registration.

AN INVESTMENT IN THE COMPANY IS SPECULATIVE AND INVOLVES A HIGH DEGREE OF RISK, INCLUDING THE POSSIBLE LOSS OF THE ENTIRE INVESTMENT, AND EACH INVESTOR SHOULD CAREFULLY READ AND CONSIDER THE FOLLOWING RISK FACTORS AND ALL MATTERS SPECIFIED IN THESE SUBSCRIPTION DOCUMENTS IN DETERMINING WHETHER OR NOT TO INVEST IN THE COMPANY. THE FOLLOWING FACTORS ARE NOT AN ALL-INCLUSIVE LIST OF POSSIBLE RISKS INHERENT IN THE OFFERING.

**Changes to the U.S. healthcare environment may not be favorable to us.** Over a number of years, the U.S. healthcare industry has undergone significant changes designed to increase access to medical care, improve safety and patient outcomes, contain costs, and increase efficiencies.

13

These changes include adoption of the Patient Protection and Affordable Care Act, a general decline in Medicare and Medicaid reimbursement levels, efforts by healthcare insurance companies to limit or reduce payments to pharmacies and providers, the basis for payments beginning to transition from a fee-for-service model to value-based payments and risk-sharing models, and the industry shifting away from traditional healthcare venues like hospitals and into clinics, physician offices and patients' homes.

We expect the U.S. healthcare industry to continue to change significantly in the future. Possible changes include repeal and replacement of major parts of the Patient Protection and Affordable Care Act, further reduction or limitations on governmental funding at the state or federal level, efforts by healthcare insurance companies to further limit payments for products and services or changes in legislation or regulations governing prescription pharmaceutical pricing, healthcare services or mandated benefits. These possible changes, and the uncertainty surrounding these possible changes, may cause healthcare industry participants to reduce the amount of products and services they purchase from us or the price they are willing to pay for our products and services, which could adversely affect us.

**The health care industry is experiencing changes that could materially adversely affect our business.** The health care industry is highly regulated and subject to changing political, economic and regulatory influences. In recent years, the health care industry has undergone, and is in the process of undergoing, significant changes driven by various efforts to reduce costs, including, among other things: trends toward managed care; consolidation of health care distribution companies; consolidation of health care manufacturers; collective purchasing arrangements and consolidation among office-based health care practitioners; and changes in reimbursements to customers, as well as growing enforcement activities (and related monetary recoveries) by governmental officials. Both our profitability and the profitability of our customers may be materially adversely affected by laws and regulations reducing reimbursement rates for pharmaceuticals and/or medical treatments or services, changes to the methodology by which reimbursement levels are determined. If we are unable to react effectively to these and other changes in the health care industry, our financial results could be materially adversely affected.

**We face inherent risk of exposure to product liability, intellectual property infringement and other claims in the event that the use of the products we sell results in injury.** Our business involves a risk of product liability, intellectual property infringement and other claims in the ordinary course of business, and from time to time it is possible we could be named as a defendant in cases as a result of our distribution of products. In addition, our reputation could be adversely affected by negative publicity surrounding such events regardless of whether or not claims against us are successful. We have various insurance policies, including product liability insurance, covering risks and in amounts that we consider adequate. In cases involving potential lawsuits in connection with products manufactured by others, the manufacturer of the product may provide us with indemnification. There can be no assurance that the insurance coverage we maintain is sufficient or will be available in adequate amounts or at a reasonable cost, or that indemnification agreements will provide us with adequate protection. A successful claim brought against us in excess of available insurance or not covered by indemnification agreements, or any claim that

14

results in significant adverse publicity against us, could have a material adverse effect on our business and our reputation.

**Consolidation in the U.S. healthcare industry may negatively impact our results of operations.** In recent years, U.S. healthcare industry participants, including distributors, manufacturers, suppliers, healthcare providers, insurers and pharmacy chains, have consolidated or formed strategic alliances. Consolidations create larger enterprises with greater negotiating power.

Consolidation in the U.S. healthcare industry has also resulted in increased competition by direct manufacturers, large national distributors, and drug wholesalers, and may result in lower customer pricing and/or higher operating costs. Additionally, changes in ownership of physician practices may erode the Company's customer base. Continued consolidation in the healthcare industry could result in the following:

- potential new entrants to the markets the Company serves;
- provider networks created through consolidation among physician provider groups, long-term care facilities, and other alternate site providers may shift purchasing decisions to entities or persons with whom the Company has no current relationship;
- national hospital distributors, drug wholesale distributors, and healthcare manufacturers may focus their efforts more directly on the Company's markets;
- competitors obtaining exclusive rights to market products to the Company's customers; and
- hospitals forming alliances with long-term care facilities or physician practices to create health systems which may look to hospital distributors and manufacturers to supply their affiliates.

**We depend on certain suppliers to make their raw materials and products available to us and are subject to fluctuations in costs of raw materials and products.** We depend on the availability of various components and raw materials supplied by others for our operations. In some instances, for reasons of quality assurance, cost effectiveness, or availability, we procure certain components and raw materials from a sole supplier. Any of our supplier relationships could be interrupted or become less favorable due to events beyond our control, including natural disasters, U.S. or international foreign policy, including tariffs, or could be terminated. In addition, due to regulations and requirements of the FDA regarding the manufacture of our products, that currently exist or may exist in the future, we may not be able to quickly establish additional or replacement sources for certain components or materials. A sustained supply reduction or interruption, and an inability to develop alternative sources for such supply, could have an adverse effect on our business.

Our manufacturing businesses use oil-based resins, pulp, cotton, latex, and other commodities as raw materials in many products. Prices of oil and gas also affect our distribution and transportation costs. Prices of these commodities are volatile and can fluctuate significantly, causing our costs to produce and distribute our products to fluctuate. Due to competitive dynamics and contractual limitations, we may be unable to pass along cost increases through higher prices. If we cannot fully offset cost increases through other cost reductions, or recover these costs through price increases or surcharges, our results of operations could be adversely affected.

15

**Expansion of GPO or hospital purchasing power and the multi-tiered costing structure may place the Company at a competitive disadvantage.** The medical products industry is subject to a multi-tiered costing structure, which can vary by manufacturer and/or product. Under this structure, certain competitors can obtain more favorable prices for medical products than the Company. The multi-tiered costing structure continues to expand as many large health systems and others with significant purchasing power, such as GPOs, demand more favorable pricing terms. This may threaten the Company's ability to compete effectively, which would in turn negatively impact the Company's results of operations. Although the Company seeks to obtain similar terms from manufacturers and obtain access to lower prices demanded by GPO contracts or other contracts, management cannot assure such terms will be obtained or contracts will be executed.

**Because there is no market for the Company's stock, you may not be able to sell your shares.** There is currently no, and there may never be any, secondary market trading in the Preferred Stock, and investors' ability to sell the Preferred Stock is further limited by transfer restrictions under applicable securities laws and the terms of the subscription agreement. Investors may never be able to sell the Preferred Stock or recover any part of your investment, unless the Company conducts a subsequent public offering or a sale of the Company or its assets, none of which things the Company has any current plans to do.

**The Preferred Stock has no voting rights.** Shares of Preferred Stock are non-voting shares. While the board of directors seeks to consider and represent the interests of all investors, holders of the Preferred Stock will not be able to cast votes representing their own interests in matters submitted to a vote of members, including election of members of the board of directors.

**There is no guarantee of return or preference of dividend payments.** No assurance can be given that an investor will realize a substantial return on investment, or any return at all, or that an investor will not lose a substantial portion or all of the investment. Further, while a purchaser of the Preferred Stock generally expects to receive a preference on payments of dividends, no assurance can be given that the Company will be able to pay the preference, and it is possible that the preference may not be paid at all.

**We have not retained an independent party to sell the Offering and the failure of our officers to sell the Offering may result in a shortage of operating funds.** Officers of the Company are offering our shares on a 'best-efforts' basis. We have not contracted with an underwriter, placement agent, or other person to purchase or sell all, or a portion, of the Preferred Stock and there is no assurance that we can sell all or any of the Preferred Stock. Further, if we had hired an underwriter, placement agent, or other independent person to sell the Offering, that person would have conducted an independent due diligence examination into our business, but since we have not done so, investors are not able to rely on the results of any such examination.

**The Company is reliant on key executives and personnel.** The Company's business, development and prospects are highly dependent upon the continued services and performance of Gregory Christmas, the Company's CEO. The experience, technical skills and relationships of Mr. Christmas provide the Company with a competitive advantage. The Company believes that the

16

loss of services of Mr. Christmas, or failure to attract and retain necessary personnel, could have a material adverse impact on the business, development, financial condition, results of operations and prospects of the Company. The Company does not currently have a plan for replacing any of these key persons, and there is currently no “key man” insurance in place in respect to Mr. Christmas. The Company may not have the financial and human resources to succeed if it loses the services of any of its key personnel due to death, disability, or other causes.

**The Company has only commenced initial operations.** The Company was incorporated as a California corporation in June 2016. It has been in the research and development phase since that time, until this calendar year 2019, when it commenced initial operations to begin sales of its first product. Because the Company is in a very early stage, it has earned very minimal revenue and profits. There is no assurance that it will ever earn significant revenues or profits. As a new enterprise, the Company is likely to be subject to risks its management has not anticipated.

**Financial information has been prepared by the Company.** The Company has not retained an independent third party to opine on the projected amount of funds needed to open and operate the Company. The Company prepared its financial statements and projections with the assistance of an accountant, but they have not been reviewed or audited by any qualified professional. Although the Company engaged consultants knowledgeable in bookkeeping and Company management, based its assumptions upon research, and endeavored to make financial statements as accurate and clear as possible, the statements may contain errors and may lead investors to make false assumptions about the financial status of the Company.

**Competition may negatively impact the Company’s ability to grow.** While, as far as the Company is aware, there is limited competition for its product in the medical device industry, this may change, as a result of which it may not be possible for the Company to win new contracts or operate profitably. Additionally, the Company will be competing for advertising sales in an extremely competitive environment against much larger, better resourced and more experienced companies and there is no guarantee that the Company will be able to successfully obtain or maintain market share for these advertising sales.

**The Company may not successfully manage its growth.** As set out in this document, the Company intends to carry out certain expansion strategies. The Company’s growth and future success will be dependent to some extent on the successful completion of the expansion strategies and the sufficiency of demand for the Company’s products and services. The execution of the Company’s expansion strategies may also place a strain on its managerial, operational and financial reserves. Should the Company fail to implement such expansion strategies or should there be insufficient demand for the Company’s products and services, the Company’s business operations, financial performance and prospects may be adversely affected.

**The Company’s officers and directors have limited experience managing a company in this business.** While our officers and directors have experience working with startups, larger companies, and governmental agencies in both administrative and operations roles, they have no prior experience managing a company of this type, or any company at all. Our ability to operate

17

successfully may depend on our ability to attract and retain qualified personnel, who may be in great demand.

**Company May Require Additional Funds.** The Company currently anticipates that the net proceeds of this Offering, assuming the Company raises a significant portion thereof, will be sufficient to meet its anticipated needs for working capital and other cash requirements for the foreseeable future. However, the Company may need to raise additional funds to build or operate. There can be no assurance that additional financing will be available on terms favorable to the Company, or at all. If adequate funds are not available or are not available on acceptable terms, the Company's ability to fund its operations would be significantly limited. Such limitation may have a material adverse effect on the Company's business, operating results and financial condition.

**Company's Operating Costs May Rise.** The Company has budgeted for a wide range of operating costs based on current conditions; but unforeseen conditions could cause operating costs to rise substantially.

**Certain Factors May Affect Future Success.** Any continued future success that the Company might enjoy will depend upon many factors including factors beyond our control and/or which cannot be predicted at this time. These factors may include but are not limited to: changes in general economic conditions; changes in the regulatory environment that makes it more difficult to operate as planned; our ability to expand our customer base and retain key customers; and reduced margins caused by competitive pressures. These conditions may have a material adverse effect upon our business, operating results, and financial condition.

**Control of the Company.** Control of the Company and all of its operations rest solely with the management and Board of Directors, upon whose judgment and skills investors must rely.

**Legal Counsel has not independently verified the statements in this Offering.** The Company has retained legal counsel to provide guidance on securities compliance aspects of this Offering, including the preparation of this Offering. However, the Company's legal counsel has not conducted a due diligence review of any of the factual matters covered in this Offering but has relied on information provided by the Company. Investors should seek their own legal counsel in connection with an investment in the Company.

**Tax Risks.** No representation or warranty of any kind is made by the Company, the officers, directors, counsel to the Company, or any other professional advisors thereto with respect to any tax consequences of any investment in the Company. EACH PROSPECTIVE INVESTOR SHOULD SEEK THE INVESTOR'S OWN TAX ADVICE CONCERNING THE TAX CONSEQUENCES OF AN INVESTMENT IN THE COMPANY.

18

**Federal Tax Considerations.** The following summary describes the material United States federal income tax consequences of the purchase, ownership, and disposition of the Shares and certain other matters, but does not purport to be a complete analysis of all potential tax considerations. In particular, the following summary does not address potential state, local, or foreign tax considerations associated with owning the Shares, and does not address any tax considerations that may apply to any prospective shareholder's particular circumstances, including any circumstances unique to corporations, tax-exempt entities, partnerships, trusts, or ESOPs. No assurance can be given that the Internal Revenue Service ('IRS') will agree with the views expressed in this summary, or that a court will not sustain any challenge by the IRS in the event of litigation. This summary of the material United States federal income tax considerations is for general information only and is not tax advice. Each prospective shareholder is urged to consult its, his or her own tax advisor to determine the federal, state, local, foreign and other tax consequences of the purchase, 34 ownership and disposition of the Shares in light of the prospective shareholder's particular circumstances.

**Treatment of Dividend Payments.** The dividends received by holders of the Shares will be includable in gross income and taxable as ordinary income for U.S. federal income tax purposes at the time such dividend is paid or accrued in accordance with such holder's regular method of tax accounting. In addition, payments of dividends should be treated as portfolio income under the passive loss rules. As portfolio income, these payments may not be offset by losses from a passive activity. For individuals, qualified dividends are subject to tax at rates up to 20 percent. The Company will report on an annual basis any dividends paid with respect to the Shares to each shareholder on a Form 1099-DIV.

**Backup Withholding.** Under federal income tax law, a holder of Shares may be subject to 'backup withholding' under certain circumstances. Backup withholding applies to a shareholder who is a United States person if the shareholder, among other things, (i) fails to furnish his social security number or other taxpayer identification number ('TIN') to the Company, (ii) furnishes the Company an incorrect TIN, (iii) fails to report properly interest and dividends, or (iv) under certain circumstances, fails to provide the Company with a certified statement, signed under penalties of perjury, that the TIN provided to the Company is correct and that the holder is not subject to backup withholding. The backup withholding rate is 24% of 'reportable payments.' Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules from a payment to a United States person generally will be allowed as a refund or as a credit against that holder's U.S. federal income tax liability, provided the requisite procedures are followed. Potential investors should consult their tax advisors for additional information concerning the potential application of backup withholding to dividend payments received by them as a result of owning Shares.

**Sale, Exchange, Redemption or Retirement of Shares.** Assuming you hold Shares as a capital asset, you generally will recognize capital gain or loss upon a sale, exchange, redemption (to the

19

extent the redemption is not treated as a dividend), retirement or other taxable disposition of Shares measured by the difference, if any, between (i) the amount of cash and the fair market value of any property received for the Shares, and (ii) the your adjusted tax basis in the Shares. The gain or loss will be long-term capital gain or loss if the Shares have been held for more than one year at the time of the sale or exchange. Long-term capital gains of non-corporate holders may be eligible for reduced rates of taxation. The deductibility of capital losses by both corporate and non-corporate holders is subject to limitations. A Shareholder’s adjusted basis in the Shares generally will be the amount paid for the Shares, provided that a Shareholder’s basis may be different if the Shares were received by gift or inheritance, or if certain other adjustments to the basis of Shares have been made.

**Net Investment Income Tax.** Certain U.S. persons who are individuals, estates or trusts to pay an additional 3.8% net investment income tax. This tax generally would apply to dividends on and capital gains from the sale or exchange of Shares and would be in addition to the dividend taxes and taxes on capital gains described above. Prospective investors should consult their tax advisors regarding the effect, if any, of the net investment income tax on the ownership or disposition of the Shares.

**State, Local, and Foreign Taxes.** In addition to the federal income tax aspects described above, prospective investors should consider potential state, local, and foreign tax consequences of an investment in the Shares. Each investor is urged to consult his own tax advisor to determine the impact any such taxes may have on the investor’s unique tax situation.

**Revisions to Use of Offering Proceeds.** It is possible that the use of the proceeds will be revised by management. Management will have significant flexibility in applying the net proceeds of this offering within the scope of the business of the Company. The failure of management to apply such funds effectively could have a material adverse effect on the Company’s business, prospects, financial condition, and results of operations.

# **(g) The minimum target offering amount and the deadline to reach the minimum target offering amount.**

The minimum target offering amount is $50,000, and the deadline to reach this amount is April 30, 2023.

If the sum of the investment commitments does not equal or exceed the minimum target offering amount at the offering deadline, no securities will be sold in the offering, investment commitments will be cancelled, and committed funds will be returned.

We plan for this offering to have a “rolling close.” Once we meet the minimum target offering amount, that amount will be closed, and those funds will be released to us. Before the funds investors have committed are released to us, such investors will be notified that the minimum

20

portion of our offering will be closed. Please see Item (h) below for more detail on the rolling close.

# **(h) Whether the issuer will accept investments in excess of the minimum target offering amount and, if so, the maximum amount that the issuer will accept and how oversubscriptions will be allocated, such as on a pro-rata, first come-first served, or other basis.**

We will accept investments in excess of the minimum target offering amount, up to a total of $1,000,000 (our maximum target offering amount). Oversubscriptions will be allocated on a first-come, first-served basis.

As described in Item (g) above, once we reach our minimum target offering amount (First Milestone), we will close that amount and those funds will be released to us. After that closing, we plan to continue our offering and to have additional closings once we have raised the total amounts listed below. Once we reach each of the below amounts (Milestones), that amount will be closed, and those funds will be released to us. Investors will be notified of each closing before the funds they have committed are released to us. Once we reach our maximum target offering amount (Tenth Milestone) or our offering deadline, whichever comes first, our offering will end and all funds that have been committed but not yet released to us will then be released to us (provided we have raised at least our minimum target offering amount).

# **Target Milestones:**

First Milestone: $50,000 (minimum target offering amount).

Second Milestone: $100,000 (additional $50,000 raised).

Third Milestone: $200,000 (additional $100,000 raised).

Fourth Milestone: $300,000 (additional $100,000 raised).

Fifth Milestone: $400,000 (additional $100,000 raised).

Sixth Milestone: $500,000 (additional $100,000 raised).

Seventh Milestone: $600,000 (additional $100,000 raised).

Eighth Milestone: $700,000 (additional $100,000 raised).

Ninth Milestone: $800,000 (additional $100,000 raised).

Tenth Milestone: $1,000,000 (additional $200,000 raised).

# **(i) A description of the purpose and intended use of the offering proceeds.**

MedFire Innovations, Inc., is seeking to raise up to $1,000,000 Class A Preferred Shares in this development phase to fund the growth and expansion of our Company.

21

The Company intends to use the proceeds raised from the crowdfunding 2023 campaign as follows:

**FUNDRAISING NEEDS:** MedFire Innovations is seeking to raise up to $1,000,000 via equity Class A Preferred shares.

| $300,000: | Research & Development |
| --- | --- |
| $150,000: | Marketing & Advertising |
| $200,000: | Hiring additional Sales and Marketing Personnel |
| $100,000: | On-going operations and reserves |
| $100,000: | Product & Device manufacturing |
| $100,000: | Trade-show Marketing |
| $50,000: | Website - Design, functionality, and applications |

**The minimum target offering amount and the deadline to reach the minimum target offering amount.** The minimum target offering amount is $50,000, and the deadline to reach this amount is April 30, 2023. If the sum of the investment commitments does not equal or exceed the minimum target offering amount at the offering deadline, no securities will be sold in this Regulation Crowdfunding offering, investment commitments will be cancelled, and committed funds will be returned. We plan for this offering to have a “rolling close.” Once we meet the minimum target offering amount, that amount will be closed, and those funds will be released to us. Before the funds investors have committed are released to us, such investors will be notified that the minimum portion of our offering will be closed. Oversubscriptions will be allocated on a first-come, first-served basis.

**The closings will occur at milestone increments, as shown below.** Once we reach our maximum target offering amount (Tenth Milestone) or our offering deadline, whichever comes first, our offering will end and all funds that have been committed but not yet released to us will then be released to us (provided that we have raised at least our minimum target offering amount).

**Description of the purpose and intended use of the offering proceeds.** MedFire Innovations will use the proceeds of this Regulation Crowdfunding Offering to increase our research and development of current and new innovations, products, and devices. We also intend on launching a targeted digital media and marketing campaign aimed at building a large recurring and new customer base for all three of our divisions and initiating radio and television advertising for our Jobs and Expo divisions. Additionally, funds will be used to hire additional sales and research staff, and to build out our manufacturing and distribution capabilities, and for acquiring new laboratory and office space.

**First Milestone:** $50,000 (minimum target offering amount). When MedFire meets the First Milestone, it plans to use the proceeds to introduce our newest device(s) into the healthcare markets in the United States. We will do this by using multiple marketing strategies that include direct sales, digital advertising, and to complete the buildout of our website platform(s).

22

| Category | Campaign Total | Milestone 1 (Minimum Target Amount) |
| --- | --- | --- |
| Marketing of MedFire Innovations (including: Direct sales, digital, print, radio, and video advertising). | $130,000 | $30,000 |
| Website Development and maintenance | $20,000 | $20,000 |

Second Milestone: $100,000 (additional $50,000 raised). When MedFire reaches the Second Milestone, it plans to use the proceeds for on-going marketing of our current products, and to continue our research and development of our newest product in development.

| Category | Campaign Total | Milestone 2 |
| --- | --- | --- |
| Marketing of MedFire Innovations, et al (including: Direct sales, digital, print, radio, and video advertising). | $130,000 | $25,000 |
| Research & Development of current and new projects (including: costs associated with development, clinical studies, testing in various categories, regulatory compliance, prototype development, legal and administrative costs). | $375,000 | $25,000 |

Third Milestone: $200,000 (additional $100,000 raised). When MedFire reaches the Third Milestone, it plans to use the proceeds to complete the research and development of our newest device our Company has currently in the final phase of development, and to enter into the application phase of this device.

| Category | Campaign Total | Milestone 3 |
| --- | --- | --- |
| Research & Development of current and new projects |  |  |

23

| (including: costs associated with development, clinical studies, testing in various categories, regulatory compliance, prototype development, legal and administrative costs). | $375,000 | $100,000 |
| --- | --- | --- |

Fourth Milestone: $300,000 (additional $100,000 raised). When MedFire reaches the Fourth Milestone, it plans to use the proceeds to complete the research and development and the final phase device testing and complete the regulatory application process for the device.

| Category | Campaign Total | Milestone 4 |
| --- | --- | --- |
| Research & Development of current and new projects (including: costs associated with development, clinical studies, testing in various categories, regulatory compliance, prototype development, legal and administrative costs). | $325,000 | $100,000 |

Fifth Milestone: $400,000 (additional $100,000 raised). When MedFire reaches the Fifth Milestone, it plans to use the proceeds to develop and use trade-show marketing to introduce our product(s) to various trade groups to generate sales and build market share. Additional funds in this milestone will be used for various forms of marketing of our product(s).

| Category | Campaign Total | Milestone 5 |
| --- | --- | --- |
| Marketing of MedFire Innovations, et al (including: Direct sales, digital, print, radio, and video advertising). | $130,000 | $25,000 |
| Trade - Show Marketing (includes all MedFire products and services) | $125,000 | $75,000 |

24

Sixth Milestone: $500,000 (additional $100,000 raised). When MedFire reaches the Sixth Milestone, it plans to use the proceeds to hire additional sales and marketing staff.

| Category | Campaign Total | Milestone 6 |
| --- | --- | --- |
| Hiring of Marketing Staff for MedFire Innovations (Direct Sales) | $150,000 | $100,000 |

Seventh Milestone: $600,000 (additional $100,000 raised). When MedFire reaches the Seventh Milestone, it plans to use the proceeds to continue with advertising and marketing of our various products and company divisions; and to include an increase in trade-show marketing through various industry tradeshows.

| Category | Campaign Total | Milestone 7 |
| --- | --- | --- |
| Hiring of Marketing Staff for MedFire Innovations (including: Marketing staff) | $150,000 | $50,000 |
| Trade - Show Marketing (includes all MedFire products and services) | $125,000 | $50,000 |

Eighth Milestone: $700,000 (additional $100,000 raised). When MedFire reaches the Eighth Milestone, it plans to use the proceeds to move forward with research and development of new innovations currently in our proposal catalog.

| Category | Campaign Total | Milestone 8 |
| --- | --- | --- |
| Research & Development of current and new projects (including: costs associated with development, clinical studies, testing in various categories, regulatory compliance, prototype development, legal and administrative costs). | $375,000 | $100,000 |

25

Ninth Milestone: $800,000 (additional $100,000 raised). When MedFire reaches the Ninth Milestone, it plans to use the proceeds to manufacture additional product necessary from sales of our product(s) and devices derived from our sales and marketing efforts.

| Category | Campaign Total | Milestone 9 |
| --- | --- | --- |
| Manufacturing of products developed for MedFire Innovations (additional money for additional manufacturing needs to supply product to customers) | $100,000 | $100,000 |

Tenth Milestone: $1,000,000 (additional $200,000 raised). When MedFire reaches the Tenth Milestone, it plans to use the proceeds to continue with sales and marketing, ongoing research and development, and to keep some monies in our reserves.

| Category | Campaign Total | Milestone 10 |
| --- | --- | --- |
| Marketing of MedFire Innovations, et al (including: Direct sales, digital, print, radio, and video advertising). | $130,000 | $50,000 |
| Research & Development of current and new projects (including: costs associated with development, clinical studies, testing in various categories, regulatory compliance, prototype development, legal and administrative costs). | $375,000 | $50,000 |
| Reserve Monies for MedFire Innovations (monies to be used for general purposes, or, for unseen needs during the course of normal operations) | $100,000 | $100,000 |

26

**Note:** A significant amount of our capital raise will be used for current and ongoing research and development of product(s) and devices. Below is a breakdown of the proposed use of funds for one of our devices that is in the final phase of development and testing to finalize regulatory requirements of use. These funds to be used for this final phase of development are noted in our Research & Development budget of $300,000.

1. Product Development (various costs associated with all development) $50,000
2. Pilot Production for Clinical Studies (1,000 units) $15,000
3. Benchtop Testing $35,000
4. Biocompatibility Testing $15,000
5. Clinical Testing $50,000
6. Regulatory compliance $20,000
7. Production molds $50,000
8. Legal and Administrative costs $10,000

In summary, if the Company raises the full maximum target offering amount, it will be able to initiate the completion of research and development for multiple products and devices the Company is currently selling, and in final development. Additional funds raised during this period will allow for continued research and development of new products and devices being developed to sell into the healthcare markets, and into other related markets. Additionally, if the full maximum target offering amount is met, our Company will be able to increase sales and staff, and maximize our sales, marketing, and advertising efforts.

#### Breakdown of All Milestones for MedFire Innovations

| Category | Campaign Total | All Milestones |
| --- | --- | --- |
| Marketing of MedFire Innovations, et al (including: Direct sales, digital, print, radio, and video advertising). | $130,000 | $130,000 |
| Website Development and maintenance | $20,000 | $20,000 |
| Research & Development of current and new projects (including: costs associated with development, clinical studies, testing in various categories, regulatory compliance, prototype development, legal and administrative costs). | $375,000 | $375,000 |

27

| Trade - Show Marketing (includes all MedFire products and services) | $125,000 | $125,000 |
| --- | --- | --- |
| Hiring of Marketing Staff for MedFire Innovations (including: Marketing staff) | $150,000 | $150,000 |
| Manufacturing of products developed for MedFire Innovations (additional money for additional manufacturing needs to supply product to customers) | $100,000 | $100,000 |
| Reserve Monies for MedFire Innovations (monies to be used for general purposes, or, for unseen needs during the course of normal operations) | $100,000 | $100,000 |
| Totals | $1,000,000 | $1,000,000 |

# **(j) A description of the process to complete the transaction or cancel an investment commitment.**

Investors may cancel an investment commitment until 48 hours prior to the deadline identified in our offering materials.

This offering’s intermediary, MiTec, PBC (under trade name Crowdfund Main Street) will notify investors when the minimum target offering amount has been met.

If we reach the minimum target offering amount prior to the deadline identified in our offering materials, we may close the offering early if we provide notice about the new offering deadline at least five business days prior to such new offering deadline (absent a material change that would require an extension of the offering and reconfirmation of the investment commitment).

If an investor does not cancel an investment commitment before the 48-hour period prior to the offering deadline, the funds will be released to us upon closing of the offering and the investor will receive securities in exchange for his or her investment.

28

The issuer may decide to terminate an offering at any time. An offering may also be cancelled if the target raise is not reached. If this occurs, the investor is entitled to a full refund. Within five business days following the cancellation of the offering, Crowdfund Main Street will

Send the investor a notification of the cancellation, disclosing the reason for the cancellation, and the refund amount that the investor is expected to receive.

Direct the refund of the investor’s funds. Please note that the company may choose not to accept an investment for any reason.

A description of the process to complete the transaction is included in the investor education materials provided on the Crowdfund Main Street platform.

**(k) A statement that if an investor does not reconfirm his or her investment commitment after a material change is made to the offering, the investor's investment commitment will be cancelled and the committed funds will be returned.**

If an investor does not reconfirm his or her investment commitment after a material change is made to the offering, the investor's investment commitment will be cancelled and the committed funds will be returned.

**(l) The price to the public of the securities or the method for determining the price.**

Each security is priced at face value.

Prior to any sale of securities, each investor shall be provided in writing the final price and all required disclosures.

**(m) A description of the ownership and capital structure of the issuer, including:**

**(1) The terms of the securities being offered and each other class of security of the issuer, including the number of securities being offered and/or outstanding, whether or not such securities have voting rights, any limitations on such voting rights, how the terms of the securities being offered may be modified and a summary of the differences between such securities and each other class of security of the issuer, and how the rights of the securities being offered may be materially limited, diluted or qualified by the rights of any other class of security of the issuer.**

29

The issuer is offering a minimum of $50,000 and a maximum of $1,000,000 in Stock (the “Equity”).

| Securities Offered: | Series A Preferred Stock |
| --- | --- |
| Purchase Price: | $10 per share (“ Original Issue Price ”). |
| Preferred Dividends: | Preferred Shareholders shall receive annual cumulative dividends, when, as, and if declared by the Board, out of any funds and assets of the Company legally available therefor. For each fiscal year, the cumulative Preferred Dividend (“ Preferred Dividend ”) shall be six percent (6%) of the Original Issue Price (prorated for any partial year of ownership and adjusted for any future stock dividends, combinations, splits, recapitalizations, and the like). Unless each Preferred Shareholder receives its entire accumulated Preferred Dividend in cash, no dividend shall be paid or declared on any Common Stock. There are no participation rights in dividends paid on the Common Stock. |
| Redemption by Shareholder: | On or after January 1, 2027, Preferred Shareholders may request redemption of shares at a per share price equal to the Original Issue Price plus any accumulated and unpaid dividends. |
| Redemption by Company: | On or after January 1, 2030, the Company may redeem any or all, or any portion of, Preferred Stock. The per share redemption price shall be equal to the Original Issue Price plus any accumulated and unpaid dividends. |
| Insufficient funds to pay redemption: | If the Company has insufficient funds to pay a redemption, it may instead issue a promissory note as the form of payment bearing interest at the rate of 5% and providing for fully amortized payments over a period of not more than two years and containing other commercially reasonable terms as determined by the Company’s discretion. If the Company fails to meet its redemption obligations for at least eight quarters, Preferred Shareholders shall have the right, as a class, to elect a majority of the Board of Directors until such time as the Company meets its obligations. |
| Liquidation preference (in the case of dissolution or sale): | After repayment of indebtedness and allowance for any reserves which are reasonably necessary for contingent or unforeseen liabilities or obligations of the Company, liquidation proceeds shall be paid as follows: |

30

|  | first, to the holders of Preferred Stock, in an amount per share equal to the Original Issue Price (subject to adjustment for any stock split or combination or other similar event) plus the amount of any accumulated but unpaid dividends thereon; second, to the holders of Common Stock. Any merger or consolidation involving the Company (unless stockholders of the Company own a majority of the voting power of the surviving or acquiring entity) or any sale, lease, transfer, exclusive license or other disposition of all or substantially all of the assets of the Company will be considered a liquidation triggering payment of the foregoing amounts. |
| --- | --- |
| Conversion: | On or after January 1, 2027, shares of Preferred Stock may be converted to Common Stock on a 1:1 basis. |
| Voting rights: | The Preferred Shareholders shall have no voting rights, except as described above. |

The above is intended to be only a summary of some of the key terms of the Offering. The above is not a complete description of the terms of the Subscription Agreement. Please see the Subscription Agreement filed with the SEC with this offering statement as **Exhibit F** for the complete terms of the investment. The above summary is qualified in its entirety by **Exhibit F**.

# **(2) A description of how the exercise of rights held by the principal shareholders of the issuer could affect the purchasers of the securities being offered.**

The Board of Directors have the absolute right to make decisions with respect to the company. It is possible that the Board of Directors will make a decision that has negative consequences for the company and therefore the investors.

# **(3) The name and ownership level of each person, as of the most recent practicable date but no earlier than 120 days prior to the date this offering statement is filed, who is the beneficial owner of 20 percent or more of the issuer's outstanding voting equity securities, calculated on the basis of voting power.**

| Name | Ownership percentage |
| --- | --- |
| Gregory Christmas | 76.63% of common shares |

31

**(4) How the securities being offered are being valued, and examples of methods for how such securities may be valued by the issuer in the future, including during subsequent corporate actions.**

The securities being offered are valued at face value.

**(5) The risks to purchasers of the securities relating to minority ownership in the issuer and the risks associated with corporate actions including additional issuances of securities, issuer repurchases of securities, a sale of the issuer or of assets of the issuer or transactions with related parties.**

The investor will have no voting rights or ownership in the company. The company's Board of Directors, the sole decision-makers for the company, could make a decision that would have negative consequences for the company, reduce the company's revenue, and reduce the investor's return. Such decisions include, but are not limited to, the issuance of additional securities, a sale of the issuer or of the assets of the issuer, and transactions with related parties.

Investors must rely upon the judgment and skills of the executive team and the Board of Directors, who are the sole decision-makers for the company. As note-holders, investors in this offering have no voting rights or ownership of the company.

The Board of Directors' interests could differ from an investor's, and the Board of Directors could make a decision that would have negative consequences for the company, reduce the company's revenue, and reduce the investor's return. Such decisions include, but are not limited to, the issuance of additional securities, and a sale of the issuer or of the assets of the issuer.

**(6) A description of the restrictions on transfer of the securities, as set forth in 17 CFR § 227.501.**

**17 CFR § 227.501 provides that the securities may not be transferred for one year after it is issued unless it is transferred:**

(i) To the issuer;

(ii) To an accredited investor;

(iii) As part of an offering registered with the SEC; or

(iv) To a member of the family of the investor or the equivalent, to a trust controlled by the investor, to a trust created for the benefit of a member of the family of the investor or the equivalent, or in connection with the death or

32

divorce of the investor or other similar circumstance.

For purposes of this Item (m)(6), the term accredited investor shall mean any person who comes within any of the categories set forth in 17 CFR § 230.501(a), or who the issuer reasonably believes comes within any of such categories, at the time of the sale of the securities to that person.

For purposes of this Item (m)(6), the term member of the family of the investor or the equivalent includes a child, stepchild, grandchild, parent, stepparent, grandparent, spouse or spousal equivalent, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law of the purchaser, and shall include adoptive relationships. For purposes of this Item (m)(6), the term spousal equivalent means a cohabitant occupying a relationship generally equivalent to that of a spouse.

(n) The name, SEC file number and Central Registration Depository (CRD) number (as applicable) of the intermediary through which the offering is being conducted.

The name of the intermediary is MiTec, PBC (under trade name Crowdfund Main Street). The SEC file number of the intermediary is 007-00133. The intermediary's CRD number is 292759.

(o) A description of the intermediary's financial interests in the issuer's transaction and in the issuer, including:

(1) The amount of compensation to be paid to the intermediary, whether as a dollar amount or a percentage of the offering amount, or a good faith estimate if the exact amount is not available at the time of the filing, for conducting the offering, including the amount of referral and any other fees associated with the offering, and

(2) Any other direct or indirect interest in the issuer held by the intermediary, or any arrangement for the intermediary to acquire such an interest.

The amount of compensation to be paid to MiTec, PBC (under trade name Crowdfund Main Street) is 6% of offering proceeds distributed to the issuer, plus third-party background check and escrow fees.

(p) A description of the material terms of any indebtedness of the issuer, including the amount, interest rate, maturity date and any other material terms.

33

### Conditional and Unconditional Obligations

Current obligations of the company are various notes to the President and CEO of the Company, and to Marshall Lane Surprise, LLC. These various notes are for monies loaned to the Company for prior operations and research and development. Additional notes are for the purchase of United States Patents and Domain names the Company believes to be assets of the Company for current and future operations, as follows:

The founder has loaned the company $89,400 ($63,400 of his personal money and $26,000 from a separate entity controlled by him as the LLC manager). Both notes are due on March 1, 2025 and are at a 5% interest rate.

The company also has a promissory note with the founder in which the company agrees to purchase 9 United States Patents and 24 domain names related to the operations of the company. The assessed value of all 9 patents and 24 internet domain names totals $100,000.00 payable in 33 monthly installments of $3,000.00 and 1 final payment of $1,000.00, starting January 1, 2022 and ending October 4, 2024.

#### The notes:

| 9 US Patents & 24 domain names | $100,000 note payable to Gregory Christmas | Due 10-1-2024 |
| --- | --- | --- |
| Loan from Greg and Kathy Christmas | $63,400 + (5% interest) | Due 3-1-2025 |
| Loan from Marshall Lane Surprise, LLC | $26,000 + (5% interest) | Due 3-1-2025 |

### (q) A description of exempt offerings conducted within the past three years.

During 2020 and 2021, MedFire Innovations, Inc., made an offering to sell equity in MedFire Innovations, Inc. This Offering was only available to residents and businesses residing in the State of California and the Offering was made by Permit by the State of California Department of Business Oversight under securities exemption 25104(h). The Offering was for Class A Preferred Shares of non-voting stock. The total raise during this time was $70,050 and 7,050 shares of Class A Preferred Stock were issued to the founder and his wife along with 5 other investors. The proceeds of this raise were used for marketing and company operations.

**(r) A description of any transaction since the beginning of the issuer's last fiscal year, or any currently proposed transaction, to which the issuer was or is to be a party and the amount involved exceeds five percent of the aggregate amount of capital raised by the issuer in reliance on section 4(a)(6) of the Securities Act during the preceding 12-month period, inclusive of the amount the issuer seeks to raise in the current offering under such section, in which**

34

any of the following persons had or is to have a direct or indirect material interest:

(1) Any director or officer of the issuer;
(2) Any person who is, as of the most recent practicable date but no earlier than 120 days prior to the date the offering statement or report is filed, the beneficial owner of 20 percent or more of the issuer's outstanding voting equity securities, calculated on the basis of voting power;
(3) If the issuer was incorporated or organized within the past three years, any promoter of the issuer; or
(4) Any member of the family of any of the foregoing persons, which includes a child, stepchild, grandchild, parent, stepparent, grandparent, spouse or spousal equivalent, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, and shall include adoptive relationships. The term spousal equivalent means a cohabitant occupying a relationship generally equivalent to that of a spouse.

Gregory and Kathleen Christmas purchased $50,000.00 of 5,000 Class A Preferred Stock during 2021 out of 500,000 authorized shares.

(s) A discussion of the issuer's financial condition, including, to the extent material, liquidity, capital resources and historical results of operations.

Each prospective investor should read the following discussion and analysis of our financial condition and results of operations together with our audited financials, which have been filed with the SEC as Exhibit D to this offering statement, and the related notes and other financial information included elsewhere in this offering. Some of the information contained in this discussion and analysis, including information regarding the strategy and plans for our business, includes forward-looking statements that involve risks and uncertainties. Prospective investors should review the risk factors stated in Items (f) and (m) above, and any risk factors described elsewhere in this offering statement, as such factors could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.

Primary Industry Background

MedFire Innovations operates primarily in the Medical Device Development and Manufacturing industry. Medical Device Industry products are essential for healthcare. Therefore, this industry is generally protected from significant revenue volatility. However, the research and development of such products can be relatively expensive, which makes this industry slightly more vulnerable to fluctuations in economic conditions.

35

The COVID-19 pandemic did disrupt the healthcare sector significantly as well as, the many industries throughout the United States and the World. The demand for such products as; ventilators and other respiratory devices, saw a significant demand upwards, and demand for other medical devices in the healthcare sector staying flat or decreasing during the first year following the start of the pandemic. As a result, the overall Medical Device Development and Manufacturing industry as a whole did see revenues decline in 2020, however, as the pandemic starts to pass and the demand for in person healthcare services is starting to increase, we believe our industry will see significant growth in the near team, and foreseeable future.

A report by IBISWorld (Medical Device Manufacturing in the US, Jan. 2022) believes the following for the overall industry. *Over the five years to 2026, the industry is expected to return to growth, with revenue increasing at an annualized rate of 3.2% to $52.7 billion. The aging baby boomer population and technology developments will continue to bolster industry growth, while the changing regulatory environment will likely support profitability. Additionally, input prices are expected to rise only slightly, resulting in a marginal increase in average industry profit (measured as earnings before interest and taxes) from 12.3% of revenue in 2021 to 12.4% in 2026.*

MedFire Innovations, Inc. believes 2023 will be a year of significant successes with multiple products and services we have developed and continue to develop for the healthcare and first-responder markets. Our Company dedicated a sizable portion of our previous year's revenues, and investments to research and development of these devices and services, thus the fruits of these financial resources and research and development will help us generating sales and revenue from these various devices and services in 2023.

## Financial Condition

Med Fire Innovations, Inc. is heavily invested currently in research and development. Most of the company's revenue and investments from prior years has gone directly to research and development of various devices and services developed by our Company, and are now, in 2023 being provided for sale to both the public and private entities and operators in the healthcare, and first-responder industries.

In the year 2020, our Company did see a significant increase in revenue to the company due to an opportunity to sell certain PPE (Personal Protective Equipment) into these sectors. The Company generated revenues in 2020 of $202,074.12 (P&L statement January through December 2020). Net Ordinary Income was $53,684.63, and Net Income was $53,687.13. Tax returns were filed with the State of California, and the IRS, with $700.00 being paid to the IRS, and $800.00 to the State of California.

In the year 2021, our Company saw a significant decrease in revenues. COVID-19 opportunities decreased significantly in 2021, and final development of marketing and development of our new devices and services increased to complete development necessary to go to market. Credit card debt was reduced, company website construction was completed, and recurring FDA registrations were paid. Overall, in 2021 we incurred a net ordinary income of (-86,496.01), and a net income of (-95,530.84).

## Liquidity Sources

Our current liquid availability of cash on hand is approximately $75,000.00 and our ability to raise additional capital through credit is strong. The President and CEO of our Company has

36

committed a total credit line of up to $200,000 in cash if necessary for current operations. In addition to existing personal credit lines, the Company has a credit rating sufficient to increase its current credit lines and for potential credit lines and loans to be granted by a financial institution. In addition, Management believes our current product lines and related services will generate significant cash flow and the new equity offering will be successful. The total equity offering is for $1 million of Class A Preferred (non-voting) shares in the Company, beginning in January 2023.

### **Conditional and Unconditional Obligations**

Current obligations of the company are various notes to the President and CEO of the Company, and to Marshall Lane Surprise, LLC. These various notes are for monies loaned to the Company for prior operations and research and development. Additional notes are for the purchased of United States Patents related to products to be sold by the Company, and for website Domain Names the Company believes to be assets of the Company for current and future operations.

#### The notes are as follows:

| 9 US Patents & 24 Domain Names | $100,000 note payable to Gregory Christmas | Due 10-1-2024 |
| --- | --- | --- |
| Loan from Greg and Kathy Christmas | $63,400 + (5% interest) | Due 3-1-2025 |
| Loan from Marshall Lane Surprise, LLC | $26,000 + (5% interest) | Due 3-1-2025 |

### **Expected Cash Flows**

The Company is now in the process of promoting sales and services developed by the Company in selling devices and products developed in previous years through our research and development. Currently, one of our devices has shown extremely positive results in testing and demonstrating inside large healthcare facilities. Additionally, our MedFire Jobs - job search engine is complete and on-line. Sales personnel have been hired and are being trained. Management believes the Company will see significant revenue generation from the job search engine, and little debt incurred on the revenues of the search engine. Management believes a conservative estimate of monthly revenues from the job search engine to be no less than $50,000 per month. Management also believes revenue and cash flows from the sale of our new device into the healthcare market to be substantial.

### **Legal Proceedings**

MedFire Innovations, Inc.'s management is not aware of any pending legal proceedings against the Company. Also, there have been no legal proceedings or judgements of any kind against the Company since its formation in 2016.

### **Relationships with key vendors and customers**

MedFire Innovations, Inc., and its managers, have secured various relationships with vendors and customers. Management currently believes all relationships with key stakeholders are intact and believe these relationships to be positive now and for the near future.

**(t) For offerings that, together with all other amounts sold under section 4(a)(6) of the Securities Act within the preceding 12-month period, have, in the aggregate, the following target offering amounts:**

37

(1) $124,000 or less, the amount of total income, taxable income and total tax, or the equivalent line items, as reported on the federal income tax returns filed by the issuer for the most recently completed year (if any), which shall be certified by the principal executive officer of the issuer to reflect accurately the information reported on the issuer's federal income tax returns, and financial statements of the issuer, which shall be certified by the principal executive officer of the issuer to be true and complete in all material respects. If financial statements of the issuer are available that have either been reviewed or audited by a public accountant that is independent of the issuer, the issuer must provide those financial statements instead and need not include the information reported on the federal income tax returns or the certifications of the principal executive officer;

(2) More than $124,000, but not more than $618,000, financial statements of the issuer reviewed by a public accountant that is independent of the issuer. If financial statements of the issuer are available that have been audited by a public accountant that is independent of the issuer, the issuer must provide those financial statements instead and need not include the reviewed financial statements; and

(3) More than $618,000 financial statements of the issuer audited by a public accountant that is independent of the issuer; provided, however, that for issuers that have not previously sold securities in reliance on section 4(a)(6) of the Securities Act (15 U.S.C. 77d(a)(6)), offerings that have a target offering amount of more than $618,000, but not more than $1,235,000 financial statements of the issuer reviewed by a public accountant that is independent of the issuer. If financial statements of the issuer are available that have been audited by a public accountant that is independent of the issuer, the issuer must provide those financial statements instead and need not include the reviewed financial statements.

The issuer's audited financial statements have been filed with the SEC with this offering statement as Exhibit D.

(u) Any matters that would have triggered disqualification under §227.503(a) but occurred before May 16, 2016. The failure to provide such disclosure shall not prevent an issuer from continuing to rely on the exemption provided by section 4(a)(6) of the Securities Act if the issuer

38

establishes that it did not know and, in the exercise of reasonable care, could not have known of the existence of the undisclosed matter or matters.

None.

# **(v) Updates regarding the progress of the issuer in meeting the target offering amount, to be provided in accordance with 17 CFR §227.203.**

As required by 17 CFR §227.203, we will make publicly available on the Crowdfund Main Street platform frequent updates regarding our progress in meeting our target offering amount. We will also file a Form C-U to disclose the total amount of securities sold in the offering no later than five business days after the offering deadline, as required by 17 CFR §227.203.

# **(w) Where on the issuer's website investors will be able to find the issuer's annual report, and the date by which such a report will be available on the issuer's website.**

We will file any required annual reports with the SEC and post the report on our website no later than 120 days after the end of each fiscal year covered by the report.

Our first annual report for this offering will be posted at www.medfireinvest.com by April 30, 2024.

We may terminate our reporting obligations in the future in accordance with Rule 202(b) of Regulation Crowdfunding (§ 227.202(b)) by (1) being required to file reports under Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended (2) filing at least one annual report pursuant to Regulation Crowdfunding and having fewer than 300 holders of record, (3) filing annual reports for three years pursuant to Regulation Crowdfunding and having total assets that do not exceed $10,000,000, (4) the repurchase of all the securities sold in this offering by the company or another party, including any payment in full of debt securities or any complete redemption of redeemable securities or (5) the liquidation or dissolution of the company in accordance with state law.

# **(x) Whether the issuer or any of its predecessors previously failed to comply with the ongoing reporting requirements of 17 CFR §227.202.**

No.

# **(y) Any material information necessary in order to make the statements made, in light of the circumstances under which they were made, not misleading.**

Please see the **Exhibits** filed with the SEC with this Form C for further information about the offering.

39

## Exhibits List

- Exhibit A: Pitch Deck
- Exhibit B: Executive Team
- Exhibit C: Use of Proceeds
- Exhibit D: Audited Financials
- Exhibit E: Possible Future Operations
- Exhibit F: Form of Subscription Agreement
- Exhibit G: Crowdfund Main Street Crowdfunding Page
- Exhibit H: Amended Articles of Incorporation
- Exhibit I: Offering Video Transcript
- Exhibit J: Jobs & Expo Video Transcript

40

**Attachment 2:** `amedpitch.pdf`

![img-0.jpeg](img-0.jpeg)

# Helping Those in
The Business of
Protecting Others

![img-1.jpeg](img-1.jpeg)

# Disclaimer

![img-2.jpeg](img-2.jpeg)

This presentation may contain forward-looking statements and information relating to, among other things, the company, its business plan and strategy, and its industry. These statements reflect management's current views with respect to future events based on information currently available and are subject to risks and uncertainties that could cause the company's actual results to differ materially. Investors are cautioned not to place undue reliance on these forward-looking statements as they contain hypothetical illustrations of mathematical principles, are meant for illustrative purposes, and they do not represent guarantees of future results, levels of activity, performance, or achievements, all of which cannot be made. Moreover, no person nor any other person or entity assumes responsibility for the accuracy and completeness of forward-looking statements and is under no duty to update any such statements to conform them to actual results.

**Copyright 2023, MedFire Innovations Inc. All rights reserved.**

The complete contents of this presentation are the intellectual property of MedFire Innovations protected by copyright and other protective laws. This presentation and no part of it can be copied or reproduced without the express written permission of MedFire Innovations Inc.

Copyright 2023, MedFire Innovations Inc. All rights reserved.

2

# Born From a Single Idea...

![img-3.jpeg](img-3.jpeg)

MedFire Innovations Inc. was born with a single idea, and it was through the creation of our first product, we found the true value in developing key relationships and strategic resources. On June 22, 2016, MedFire Innovations, was formed as a corporation in the State of California. Since this time, MedFire has developed, manufactured, and brought to market our own innovative ideas, in the form of additional products and services. Realizing the value of our key relationships and resources, we expanded our services to include helping others create products through our custom collaborative process.

Our company is rapidly building assets and intellectual property for ourselves and for our clients. Since our inception, MedFire, an FDA Registered company, has obtained ten (10) United States Patents and two (2) Registered Trademarks. Additionally, we have multiple products in development, and multiple patents pending.

Moving forward, we envision a future where those with great ideas turn to us to develop these ideas into realities. MedFire is where Doctors, Nurses, Scientists, Public Safety Professionals, Veterinarians, and the like, come to move their ideas from the drafting table to the operating table, and from scratch paper to the field. A future that is only limited to one’s imagination. This is MedFire Innovations.

Copyright 2023, MedFire Innovations Inc. All rights reserved.

3

# Creating a Culture of Innovation

![img-4.jpeg](img-4.jpeg)

**MedFire** has developed a network of creative and innovative experts to help your ideas become reality. We have created a Culture of Innovation by sharing ideas and concepts within this network of biomedical, mechanical, and electrical engineers, to manufacturers, packaging experts, technical and regulatory specialists, and finally sales and marketing professionals, all with one goal in mind - *To Bring Innovation To Life*.

![img-5.jpeg](img-5.jpeg)

MedFire Innovations helps transform ideas into safe, profitable, and innovative medical products through a rapid and systematic design process. We can provide a broad range of services to support medical device development, which includes Class I, Class II, and Class III devices. From design, to engineering and integration, to testing and transfer, we will work with you at any phase of the design process. Whether you are seeking to improve an existing device or to develop a completely new medical device, we are prepared for the challenge.

Copyright 2023, MedFire Innovations Inc. All rights reserved.

4

# Serving Those Who Protect Us

![img-6.jpeg](img-6.jpeg)

**MedFire** has developed three distinct divisions to provide an array of services to those individuals and organization dedicated to protecting those in need. Providing services to help develop products, devices, and services. Providing a dedicated platform for employers and job seeks to connect. Providing a Marketplace for Exponential Brand Growth. **MedFire Helps Those Who Are In The Business of Protecting Others.**

Careers

Innovations

Marketplace

![img-7.jpeg](img-7.jpeg)

![img-8.jpeg](img-8.jpeg)

![img-9.jpeg](img-9.jpeg)

Copyright 2023, MedFire Innovations Inc. All rights reserved.

5

# MedFire Innovations Logo

[LOGO]

MedFire

INNOVATIONS

![img-10.jpeg](img-10.jpeg)

Copyright 2023, MedFire Innovations Inc. All rights reserved.

6

# Company DNA

MedFire
INNOVATIONS

![img-11.jpeg](img-11.jpeg)

Copyright 2023, MedFire Innovations Inc. All rights reserved.

7

# The MedFire Team

![img-12.jpeg](img-12.jpeg)

**MedFire Innovations**, Incorporated is led by our **Chairman and Chief Executive Officer, Gregory Christmas**. Mr. Christmas has put together a team of individuals and groups that provide all the experience and skills necessary to ensure the success of MedFire Innovations and all its divisions. From Doctors and Nurses, to Scientists and Bioengineers, EMT's and Paramedics, Firefighters, Engineers, Machinists, Fabricators, IT Professionals, IP Professionals, Marketing Experts, and more. Our combined team is seasoned in their expertise and ready for a challenge.

![img-13.jpeg](img-13.jpeg)

Copyright 2023, MedFire Innovations Inc. All rights reserved.

8

# The Executive MedFire Team

[LOGO]

MedFire

INNOVATIONS

Gregory Christmas
President & CEO

![img-14.jpeg](img-14.jpeg)

![img-15.jpeg](img-15.jpeg)

Staci Mehl
Vice President

![img-16.jpeg](img-16.jpeg)

Andrea Siller

Bio Engineer &

Consultant

Copyright 2023, MedFire Innovations Inc. All rights reserved.

9

# The MedFire Companies

![img-0.jpeg](img-0.jpeg)

![img-1.jpeg](img-1.jpeg)

![img-2.jpeg](img-2.jpeg)

![img-3.jpeg](img-3.jpeg)

![img-4.jpeg](img-4.jpeg)

![img-5.jpeg](img-5.jpeg)

Copyright 2023, MedFire Innovations Inc. All rights reserved.

10

# MedFire Innovations

**MedFire Innovations** is our primary division, as well as the name of our Company. This division focuses on the development of our Company products, devices, and services. This division provides services to outside individuals and entities seeking various services our company provides for the development of original ideas for the medical, science, and public safety industries. Some of these services include assistance with the design and development of a device, feasibility studies, concept development, design for manufacturing, small batch prototype production, verification and validation, FDA clearance and approval, intellectual property and branding, marketing and sales, and distribution and fulfillment.

Copyright 2023, MedFire Innovations Inc. All rights reserved.

11

# WHO we help

MedFire
INNOVATIONS

![img-6.jpeg](img-6.jpeg)

Copyright 2023, MedFire Innovations Inc. All rights reserved.

12

# WHAT we do

![img-7.jpeg](img-7.jpeg)

![img-8.jpeg](img-8.jpeg)

**MedFire Innovations**, Incorporated was founded because one person wanted to help those who help others, and it is on this statement *“Protecting Those Who Are In The Business Of Protecting Others”* our company stands. Since our beginning, we have made it our mission to help bring to market the ideas that will help make our world a better and safer place. To develop ideas that protect patients and patient care providers, and those working on the front lines of public safety. We can do this because we have assembled a team of partners that are dedicated to helping make ideas become reality.

![img-9.jpeg](img-9.jpeg)

We help make Ideas become reality by using a user-oriented industrial design process based on the Design Thinking methodology. We provide a broad range of services to support medical device development, including Class I, Class II, and Class III devices - to devices used by those working on the frontlines in public safety. From initial concept, to design, to engineering and integration, to testing and transfer, we will work with you at any phase of the design process. Whether you are seeking to improve an existing device, or design and develop a completely new and innovative device, we are prepared for the challenge.

Copyright 2023, MedFire Innovations Inc. All rights reserved.

13

# HOW we do it

[LOGO]

MedFire

INNOVATIONS

Concept Development

![img-10.jpeg](img-10.jpeg)

Industrial Design

Copyright 2023, MedFire Innovations Inc. All rights reserved.

14

# Guiding Businesses

[LOGO]

MedFire
INNOVATIONS

![img-11.jpeg](img-11.jpeg)

Guiding businesses at
any stage to become
the success stories
they deserve

We are excited to present some
examples of products and devices
developed by MedFire Innovations
and in collaboration with our unique
network of innovative partners.

Copyright 2023, MedFire Innovations Inc. All rights reserved.

15

# MedFire Innovations and many more..

[LOGO]

MedFire

INNOVATIONS

![img-12.jpeg](img-12.jpeg)

Copyright 2023, MedFire Innovations Inc. All rights reserved.

16

# Industry Statistics

MedFire
INNOVATIONS

## Medical Device Manufacturing

![img-13.jpeg](img-13.jpeg)

### Medical Device Manufacturing in the United States

**$49.4bn** Medical Device Manufacturing in the US Market: Size in 2021

**6.3%** Medical Device Manufacturing in the US: Market Size Growth in 2021

**4.8%** Medical Device Manufacturing in the US: Annualized Market Size Growth 2016 - 2021

(IBISWorld, December, 8, 2020)

Copyright 2023, MedFire Innovations Inc. All rights reserved.

17

# Industry Statistics

MedFire
INNOVATIONS

## Medical Supply Wholesaling

![img-14.jpeg](img-14.jpeg)

### Medical Supplies Wholesaling
United States

**$240.2bn** Medical Supplies Wholesaling in
the US Market: Size in 2021

**2.1%** Medical Supplies Wholesaling in
the US Market: Size Growth in
2021

**2.2%** Medical Supplies Wholesaling in
the US: Annualized Market Size
Growth 2016-2021

(IBISWorld, December, 8, 2020)

Copyright 2023, MedFire Innovations Inc. All rights reserved.

18

# Revenue

## MedFire Innovations will generate revenues by:

![img-15.jpeg](img-15.jpeg)

Selling products, devices, and services developed and manufactured by MedFire Innovations.

![img-16.jpeg](img-16.jpeg)

Selling products, devices, and services designed, developed, by MedFire Innovations for contracted customers.

![img-17.jpeg](img-17.jpeg)

Providing various services including; consulting, concept and design, and development services to individuals and groups interested in product and device development for new - innovative products and devices.

![img-18.jpeg](img-18.jpeg)

Product Licensing & Royalties

Copyright 2023, MedFire Innovations Inc. All rights reserved.

19

# MedFire Jobs

![img-0.jpeg](img-0.jpeg)

![img-1.jpeg](img-1.jpeg)

![img-2.jpeg](img-2.jpeg)

**“Where Heroes Come To Get Hired”**

**MedFire Jobs** is a “niche” job search platform, focused on jobs and careers for those who currently work, or are seeking employment in the fields of Medicine, Science, Nursing, Fire and EMS, Law Enforcement, Veterinary Medicine, and other Public Safety professions. Its features include a hiring platform to assist employers with recruiting, from detailed job posting services to video interview capabilities to meet and assess applicable candidates. The platform further enables Featured Company and Featured Advertisement services that allow employers to improve visibility of their job and career offerings, and more. This tailored platform provides one-of-a-kind user experience for employers and job seekers within this industry sector.

Copyright 2023, MedFire Innovations Inc. All rights reserved.

20

# WHO we help

MedFire
INNOVATIONS

![img-3.jpeg](img-3.jpeg)

![img-4.jpeg](img-4.jpeg)

- Hospitals
- Clinics
- Physicians
- Nurses
- Medical Technicians
- EMT's & Paramedics

- Firefighters
- Public Safety Professionals
- Scientists
- Lab Technicians
- Veterinarian professions
- And more...

Copyright 2023, MedFire Innovations Inc. All rights reserved.

21

# WHAT we do

MedFire
INNOVATIONS

![img-5.jpeg](img-5.jpeg)

Provide Job Posting &
Recruitment Services

![img-6.jpeg](img-6.jpeg)

![img-7.jpeg](img-7.jpeg)

Provide services to both
Job Seekers & Employers

Provide a “niche” service to
those in the Medical,
Science, Public Safety, and
Veterinary professions

![img-8.jpeg](img-8.jpeg)

![img-9.jpeg](img-9.jpeg)

Provide direct advertising
opportunities for
companies and
employers

Copyright 2023, MedFire Innovations Inc. All rights reserved.

22

# HOW we do it

[LOGO]

MedFire

INNOVATIONS

[LOGO]

MedFireJobsTM

Networking and
Coaching Platform

![img-10.jpeg](img-10.jpeg)

Copyright 2023, MedFire Innovations Inc. All rights reserved.

23

# Industry Statistics

MedFire
INNOVATIONS

![img-11.jpeg](img-11.jpeg)

![img-12.jpeg](img-12.jpeg)

## Online Recruitment Websites

### Online Recruitment Sites In the United States

**$11.1bn** Online Recruitment Sites in the US: Market Size in 2021

**7.1%** Online Recruitment Sites in the US: Market Size Growth in 2021

**11.5%** Online Recruitment Sites in the US: Annualized Market Size Growth 2016 - 2021

According to the US Bureau of Labor Statistics, 20-24% of Americans change jobs every year, which translates to more than 41 million people searching for jobs every single year in the United States.

(IBISWorld, December, 8, 2020)

Copyright 2023, MedFire Innovations Inc. All rights reserved.

24

# Revenue

MedFire
INNOVATIONS

![img-13.jpeg](img-13.jpeg)

## MedFire Jobs will generate revenues by:

![img-14.jpeg](img-14.jpeg)

Providing Job posting services for a fee

![img-15.jpeg](img-15.jpeg)

Providing advertising opportunities for a fee to companies and employers seeking job candidates

![img-16.jpeg](img-16.jpeg)

Providing unique services such as; resume writing assistance and video interviewing

MedFireJobs

Copyright 2023, MedFire Innovations Inc. All rights reserved.

25

# Marketplace

![img-17.jpeg](img-17.jpeg)

## “A Marketplace For Exponential Brand Growth”

**MedFire Expo** is a unique online marketplace environment to foster and nurture key business relationships. The Expo will provide organizations with a place to connect sales teams with sales prospects, identify new markets, and grow brand through strategic alignment and networking. Those who use the Expo will be provided a unique visual experience providing an enhanced customer experience. Expo Members will enjoy a platform to shop for products and services that cater to those who are in the business of serving others.

Copyright 2023, MedFire Innovations Inc. All rights reserved.

26

# WHO we help

MedFire
INNOVATIONS

![img-18.jpeg](img-18.jpeg)

Companies and Individuals looking to target consumers who work in the Medical, Science, Public Safety, and Veterinary professions:

- Businesses of All Kinds (large & small)
- Retailers, wholesalers, and manufacturers
- Startups & Entrepreneurs
- Product Developers
- Service Providers
- Consumers

Copyright 2023, MedFire Innovations Inc. All rights reserved.

27

# WHAT we do

MedFire
INNOVATIONS

![img-19.jpeg](img-19.jpeg)

![img-20.jpeg](img-20.jpeg)

Provide a Marketplace between retailers, wholesalers, and manufacturers, and the medical, science, and public safety community.

Provide a “niche” to those who are targeting, and selling to those working in these professions.

Provide specialized B2B, and B2C for specialized products such as; medical devices and consumables

Copyright 2023, MedFire Innovations Inc. All rights reserved.

28

# HOW we do it

MedFire
INNOVATIONS

![img-21.jpeg](img-21.jpeg)

![img-22.jpeg](img-22.jpeg)

Copyright 2023, MedFire Innovations Inc. All rights reserved.

29

# Industry Statistics

MedFire
INNOVATIONS

![img-0.jpeg](img-0.jpeg)

![img-1.jpeg](img-1.jpeg)

## E-Commerce & Online Auctions

### E-Commerce & Online Auctions In the United States

**$619.69bn**

E-Commerce & Online
Auctions in the US: Market
Size in 2021

**4.6%**

E-Commerce & Online
Auctions in the US: Market
Size Growth in 2021

**10.7%**

E-Commerce & Online
Auctions in the US: Annualized
Market Size Growth 2016-2021

(IBISWorld, December, 8, 2020)

Copyright 2023, MedFire Innovations Inc. All rights reserved.

30

# Revenue

MedFire
INNOVATIONS

![img-2.jpeg](img-2.jpeg)

![img-3.jpeg](img-3.jpeg)

## MedFire Expo will generate revenue by:

![img-4.jpeg](img-4.jpeg)

Advertising Platform for monthly and annual fees

![img-5.jpeg](img-5.jpeg)

E-Commerce Platform for monthly and annual fees, plus percentage of sales

![img-6.jpeg](img-6.jpeg)

Direct Marketing Opportunities

![img-7.jpeg](img-7.jpeg)

Networking Platforms generating fees for training courses and lectures

![img-8.jpeg](img-8.jpeg)

Marketing and Advertising material development assistance

Copyright 2023, MedFire Innovations Inc. All rights reserved.

31

# Looking for Investors

![img-9.jpeg](img-9.jpeg)

## We are looking for investors!

**MedFire Innovations** is looking for investors to participate in our Crowd-Funding offering. Your investment will accelerate our sales and operational efforts -

*“Helping Those In The Business Of Protection Others.”*

![img-10.jpeg](img-10.jpeg)

Copyright 2023, MedFire Innovations Inc. All rights reserved.

32

# The Investment

![img-11.jpeg](img-11.jpeg)

**MedFire Innovations, Inc.**

is

**OFFERING 100,000 SHARES OF SERIES A**

**PREFERRED STOCK AT $10 PER SHARE**

**TOTAL OFFERING $1,000,000**

**Minimum Investment is $500**

Copyright 2023, MedFire Innovations Inc. All rights reserved.

33

# Dividend

## What do I receive for my investment?

### A 6% Yearly Dividend

Investor participants in this investment will receive Series A Preferred Stock. The Preferred Stock will be entitled to receive cumulative dividends at a rate of 6 percent per year.

Copyright 2023, MedFire Innovations Inc. All rights reserved.

34

# MedFire Innovations, Inc.

2425 Camino Del Rio S, Suite #125
San Diego, CA 92108 USA
(888)560-1140
medfireinfo@medfire.com
www.medfire.com

![img-12.jpeg](img-12.jpeg)

**Attachment 3:** `bmedexecteam.pdf`

# The Executive MedFire Team

MedFire
INNOVATIONS

Gregory
Christmas
President & CEO

![img-0.jpeg](img-0.jpeg)

![img-1.jpeg](img-1.jpeg)

Staci Mehl
Vice President

![img-2.jpeg](img-2.jpeg)

Andrea Siller
Bio Engineer & Consultant

Copyright 2023, MedFire Innovations Inc. All rights reserved.

# President and CEO

![img-3.jpeg](img-3.jpeg)

![img-4.jpeg](img-4.jpeg)

Gregory
Christmas
President & CEO

## Gregory Christmas - President and CEO

Gregory Christmas founded MedFire Innovations, and serves the Company as the President and Chairman of the Board of Directors. He is an experienced entrepreneur with a background in private sector business and public service in emergency operations and management, and administrative management. Prior to the founding of the company, He has extensive 30 + years of experience working in the Public Safety industry, including as a Fire Captain - Paramedic in California. Mr. Christmas holds a Bachelor of Science Degree in Business Administration and a Master of Public Administration.

![img-5.jpeg](img-5.jpeg)

Copyright 2023, MedFire Innovations Inc. All rights reserved.

# Vice President-Sales Development

![img-6.jpeg](img-6.jpeg)

![img-7.jpeg](img-7.jpeg)

**Staci Mehl**

Vice President - Sales Development

## Staci Mehl - Vice President - Sales Development

Staci Mehl is a Vice President of MedFire Innovations. She has served on the Board of Directors of MedFire since 2019. Staci functioned as an independent consultant to MedFire from 2016 to the present, and is responsible for the development of product sales for the Company. Staci holds a Bachelor’s Degree in Microbiology from Texas A&M University.

![img-8.jpeg](img-8.jpeg)

Copyright 2023, MedFire Innovations Inc. All rights reserved.

# Chief Bio Engineer & Consultant

![img-9.jpeg](img-9.jpeg)

![img-10.jpeg](img-10.jpeg)

**Andrea Siller**

Chief Bio Engineer & Consultant

## Andrea Siller - Chief Bio Engineer & Consultant

Andrea Siller is our Chief Biomedical Engineer, and regulatory consultant. Andrea is passionate for helping to improve the lives of people by applying her talents and skill in design engineering. She is extremely experienced in product design and development processes, project planning and management, quality control and regulatory compliance, and business development. Andrea won the National Entrepreneur Award (Mexico) in 2017, has been a moderator on FORBES Health Panels, has a TEDx Talk, and was recognized by Vogue UK Magazine and One Young World as part of the “Game Changers” generation.

![img-11.jpeg](img-11.jpeg)

Copyright 2023, MedFire Innovations Inc. All rights reserved.

**Attachment 4:** `cmeduse.pdf`

![img-0.jpeg](img-0.jpeg)

## Use of Proceeds

MedFire Innovations, Inc., is seeking to raise up to $1,000,000 Class A Preferred Shares in this development phase to fund the growth and expansion of our Company.

The Company intends to use the proceeds raised from the crowdfunding 2023 campaign as follows:

**FUNDRAISING NEEDS:** MedFire Innovations is seeking to raise up to $1,000,000 via equity Class A Preferred shares.

| $300,000: | Research & Development |
| --- | --- |
| $150,000: | Marketing & Advertising |
| $200,000: | Hiring additional Sales and Marketing Personnel |
| $100,000: | On-going operations and reserves |
| $100,000: | Product & Device manufacturing |
| $100,000: | Trade-show Marketing |
| $50,000: | Website - Design, functionality, and applications |

### **The minimum target offering amount and the deadline to reach the minimum target offering amount.**

The minimum target offering amount is $50,000, and the deadline to reach this amount is April 30, 2023. If the sum of the investment commitments does not equal or exceed the minimum target offering amount at the offering deadline, no securities will be sold in this Regulation Crowdfunding offering, investment commitments will be cancelled, and committed funds will be returned. We plan for this offering to have a “rolling close.” Once we meet the minimum target offering amount, that amount will be closed, and those funds will be released to us. Before the funds investors have committed are released to us, such investors will be notified that the minimum portion of our offering will be closed. Oversubscriptions will be allocated on a first-come, first-served basis.

**The closings will occur at milestone increments, as shown below.** Once we reach our maximum target offering amount (Tenth Milestone) or our offering deadline, whichever comes first, our offering will end and all funds that have been committed but not yet released to us will then be released to us (provided that we have raised at least our minimum target offering amount).

**Description of the purpose and intended use of the offering proceeds.** MedFire Innovations will use the proceeds of this Regulation Crowdfunding Offering to increase our research and development of current and new innovations, products, and devices. We also intend on launching a targeted digital media and marketing campaign aimed at building a large recurring and new customer base for all three of our divisions and initiating radio and television advertising for our Jobs and Expo divisions. Additionally, funds will be used to hire additional sales and research staff, and to build out our manufacturing and distribution capabilities, and for acquiring new laboratory and office space.

First Milestone: $50,000 (minimum target offering amount). When MedFire meets the First Milestone, it plans to use the proceeds to introduce our newest device(s) into the healthcare markets in the United States. We will do this by using multiple marketing strategies that include direct sales, digital advertising, and to complete the buildout of our website platform(s).

| Category | Campaign Total | Milestone 1 (Minimum Target Amount) |
| --- | --- | --- |
| Marketing of MedFire Innovations (including: Direct sales, digital, print, radio, and video advertising). | $130,000 | $30,000 |
| Website Development and maintenance | $20,000 | $20,000 |

Second Milestone: $100,000 (additional $50,000 raised). When MedFire reaches the Second Milestone, it plans to use the proceeds for on-going marketing of our current products, and to continue our research and development of our newest product in development.

| Category | Campaign Total | Milestone 2 |
| --- | --- | --- |
| Marketing of MedFire Innovations, et al (including: Direct sales, digital, print, radio, and video advertising). | $130,000 | $25,000 |
| Research & Development of current and new projects (including: costs associated with development, clinical studies, testing in various categories, regulatory compliance, prototype development, legal and administrative costs). | $375,000 | $25,000 |

Third Milestone: $200,000 (additional $100,000 raised). When MedFire reaches the Third Milestone, it plans to use the proceeds to complete the research and development of our newest device our Company has currently in the final phase of development, and to enter into the application phase of this device.

| Category | Campaign Total | Milestone 3 |
| --- | --- | --- |

| Research & Development of current and new projects (including: costs associated with development, clinical studies, testing in various categories, regulatory compliance, prototype development, legal and administrative costs). | $375,000 | $100,000 |
| --- | --- | --- |

Fourth Milestone: $300,000 (additional $100,000 raised). When MedFire reaches the Fourth Milestone, it plans to use the proceeds to complete the research and development and the final phase device testing and complete the regulatory application process for the device.

| Category | Campaign Total | Milestone 4 |
| --- | --- | --- |
| Research & Development of current and new projects (including: costs associated with development, clinical studies, testing in various categories, regulatory compliance, prototype development, legal and administrative costs). | $325,000 | $100,000 |

Fifth Milestone: $400,000 (additional $100,000 raised). When MedFire reaches the Fifth Milestone, it plans to use the proceeds to develop and use trade-show marketing to introduce our product(s) to various trade groups to generate sales and build market share. Additional funds in this milestone will be used for various forms of marketing of our product(s).

| Category | Campaign Total | Milestone 5 |
| --- | --- | --- |
| Marketing of MedFire Innovations, et al (including: Direct sales, digital, print, radio, and video advertising). | $130,000 | $25,000 |
| Trade - Show Marketing (includes all MedFire products and services) | $125,000 | $75,000 |

Sixth Milestone: $500,000 (additional $100,000 raised). When MedFire reaches the Sixth Milestone, it plans to use the proceeds to hire additional sales and marketing staff.

| Category | Campaign Total | Milestone 6 |
| --- | --- | --- |
| Hiring of Marketing Staff for MedFire Innovations (Direct Sales) | $150,000 | $100,000 |

Seventh Milestone: $600,000 (additional $100,000 raised). When MedFire reaches the Seventh Milestone, it plans to use the proceeds to continue with advertising and marketing of our various products and company divisions; and to include an increase in trade-show marketing through various industry tradeshows.

| Category | Campaign Total | Milestone 7 |
| --- | --- | --- |
| Hiring of Marketing Staff for MedFire Innovations (including: Marketing staff) | $150,000 | $50,000 |
| Trade - Show Marketing (includes all MedFire products and services) | $125,000 | $50,000 |

Eighth Milestone: $700,000 (additional $100,000 raised). When MedFire reaches the Eighth Milestone, it plans to use the proceeds to move forward with research and development of new innovations currently in our proposal catalog.

| Category | Campaign Total | Milestone 8 |
| --- | --- | --- |
| Research & Development of current and new projects (including: costs associated with development, clinical studies, testing in various categories, regulatory compliance, prototype development, legal and administrative costs). | $375,000 | $100,000 |

Ninth Milestone: $800,000 (additional $100,000 raised). When MedFire reaches the Ninth Milestone, it plans to use the proceeds to manufacture additional product necessary from sales of our product(s) and devices derived from our sales and marketing efforts.

| Category | Campaign Total | Milestone 9 |
| --- | --- | --- |
| Manufacturing of products developed for MedFire Innovations (additional money for additional manufacturing needs to supply product to customers) | $100,000 | $100,000 |

Tenth Milestone: $1,000,000 (additional $200,000 raised). When MedFire reaches the Tenth Milestone, it plans to use the proceeds to continue with sales and marketing, ongoing research and development, and to keep some monies in our reserves.

| Category | Campaign Total | Milestone 10 |
| --- | --- | --- |
| Marketing of MedFire Innovations, et al (including: Direct sales, digital, print, radio, and video advertising). | $130,000 | $50,000 |
| Research & Development of current and new projects (including: costs associated with development, clinical studies, testing in various categories, regulatory compliance, prototype development, legal and administrative costs). | $375,000 | $50,000 |
| Reserve Monies for MedFire Innovations (monies to be used for general purposes, or, for unseen needs during the course of normal operations) | $100,000 | $100,000 |

**Note:** A significant amount of our capital raise will be used for current and ongoing research and development of product(s) and devices. Below is a breakdown of the proposed use of funds for one of our devices that is in the final phase of development and testing to finalize regulatory requirements of use. These funds to be used for this final phase of development are noted in our Research & Development budget of $300,000.

1. Product Development (various costs associated with all development) $50,000
2. Pilot Production for Clinical Studies (1,000 units) $15,000

3. Benchtop Testing $35,000
4. Biocompatibility Testing $15,000
5. Clinical Testing $50,000
6. Regulatory compliance $20,000
7. Production molds $50,000
8. Legal and Administrative costs $10,000

In summary, if the Company raises the full maximum target offering amount, it will be able to initiate the completion of research and development for multiple products and devices the Company is currently selling, and in final development. Additional funds raised during this period will allow for continued research and development of new products and devices being developed to sell into the healthcare markets, and into other related markets. Additionally, if the full maximum target offering amount is met, our Company will be able to increase sales and staff, and maximize our sales, marketing, and advertising efforts.

# Breakdown of All Milestones for MedFire Innovations

| Category | Campaign Total | All Milestones |
| --- | --- | --- |
| Marketing of MedFire Innovations, et al (including: Direct sales, digital, print, radio, and video advertising). | $130,000 | $130,000 |
| Website Development and maintenance | $20,000 | $20,000 |
| Research & Development of current and new projects (including: costs associated with development, clinical studies, testing in various categories, regulatory compliance, prototype development, legal and administrative costs). | $375,000 | $375,000 |
| Trade - Show Marketing (includes all MedFire products and services) | $125,000 | $125,000 |
| Hiring of Marketing Staff for MedFire Innovations (including: Marketing staff) | $150,000 | $150,000 |
| Manufacturing of products developed for MedFire Innovations (additional | $100,000 | $100,000 |

| money for additional manufacturing needs to supply product to customers) |  |  |
| --- | --- | --- |
| Reserve Monies for MedFire Innovations (monies to be used for general purposes, or, for unseen needs during the course of normal operations) | $100,000 | $100,000 |
| Totals | $1,000,000 | $1,000,000 |

**Attachment 5:** `dmedaudit.pdf`

## Exhibit D Audited Financials

# MEDFIRE INNOVATION, INC.

# FINANCIAL STATEMENTS

# DECEMBER 31, 2021 AND 2020 (Restated)

# TABLE OF CONTENTS

|  | PAGE |
| --- | --- |
| Independent Auditors' Report | 3 - 4 |
| Balance Sheets | 5 |
| Statements of Income and Retained Earnings (Deficit) | 6 |
| Statements of Cash Flows | 7 |
| Notes to the Financial Statements | 8 - 15 |

# Matranga & Company

An Accountancy Corporation

# INDEPENDENT AUDITORS' REPORT

To the Board of Directors

Medfire Innovations, Inc.

San Diego, California

We have audited the accompanying financial statements of Medfire Innovations, Inc., a California corporation, which comprise the balance sheet of as of December 31, 2021 and 2020 (restated) and the related statements of income and retained earnings and cash flows for the years then ended and the related notes to the financial statements.

# Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to error or fraud.

# Auditor's Responsibility

Our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting principles used and the reasonableness of significant estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

6255 Lusk Blvd., Suite 150, San Diego, CA 92121 [858] 558-8100 [858] 558-8200 www.jmcpafirm.com

## Opinion

In our opinion, the financial statements referred above present fairly, in all material respects, the financial position of Medfire Innovations, Inc., as of December 31, 2021 and 2020 (restated), and the results of its operations and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

## Correction of an Error

As discussed in Note F to the financial statements, sales tax collected was misclassified as revenue resulting in the understatement in previously reported amounts for current liabilities and the overstatement of net income and retained earnings as of December 31, 2020, were discovered by management of the Company during the current year. Accordingly, amounts reported for those accounts have been restated in the 2020 financial statements now presented, and adjustments have been made to retained earnings as of December 31, 2020, to correct the error. Our opinion is not modified with respect to that matter.

Matranga & Company

San Diego, California  
February 21, 2022

# MEDFIRE INNOVATIONS, INC.

# BALANCE SHEETS

# DECEMBER 31, 2021 AND 2020

| ASSETS |  |  |
| --- | --- | --- |
|  | 2021 | (Restated) 2020 |
| Current Assets |  |  |
| Cash and cash equivalents | $27,408 | $32,059 |
| Inventory | 19,584 | 19,584 |
| Total Current Assets | 46,992 | 51,643 |
| Intangible Assets |  |  |
| Organizational costs | 1,224 | 1,224 |
| Patents | 55,675 | 44,341 |
| Trademark | 6,000 | 6,000 |
| Accumulated amortization | (9,907) | (6,933) |
| Net intangible assets | 52,992 | 44,632 |
| Total Assets | $99,984 | $96,275 |
| LIABILITIES AND SHAREHOLDERS' (DEFICIT) |  |  |
| Current Liabilities |  |  |
| Accounts payable | $ - | $ - |
| Credit cards payable | 32,998 | 16,437 |
| Sales tax payable | - | 15,006 |
| Total Current Liabilities | 32,998 | 31,443 |
| Non-Current Liabilities |  |  |
| Loan from Marshall lane, LLC (Note C) | $30,434 | $26,991 |
| Shareholder loan (Note D) | 69,596 | 65,566 |
| Due to related party (Note C) | 1,732 | 1,732 |
| Total Non-Current Liabilities | 101,762 | 94,289 |
| Total Liabilities | 134,760 | 125,732 |
| Shareholders' Equity (Deficit) |  |  |
| Common stock - 2,000,000 shares authorized, 783,000 shares issued and outstanding | 1,305 | 1,305 |
| Preferred stock - 500,000 shares authorized, 9,050 and 800 shares issued and outstanding at December 31, 2021 and 2020, respectively (Note B | 90,500 | 8,000 |
| Additional paid in capital | 41,295 | 41,295 |
| Retained equity (deficit) | (167,876) | (80,057) |
| Total Shareholders' Equity (Deficit) | (34,776) | (29,457) |
| Total Liabilities and Shareholders' Equity (Deficit) | $99,984 | $96,275 |

See independent auditors' report and accompanying notes to the financial statements.

- 5 -

# MEDFIRE INNOVATIONS, INC.  
 STATEMENTS OF INCOME AND RETAINED (DEFICIT)  
 FOR THE YEARS ENDED DECEMBER 31, 2021 AND 2020

|  | 2021 | (Restated) 2020 |
| --- | --- | --- |
| Net Revenue | $21,762 | $187,068 |
| Cost of Revenue | (17,573) | (102,687) |
| Gross margin | 4,189 | 84,381 |
| Operating Expenses | (73,411) | (29,624) |
| Operating income (loss) | (69,222) | 54,757 |
| Other Income (expense) |  |  |
| Amortization expense | (2,974) | (2,773) |
| Research and development | - | (500) |
| Interest income | 3 | 3 |
| Interest expense | (13,358) | (10,829) |
| Stock offering costs | - | (43,053) |
| Other income (expense) | (16,329) | (57,152) |
| Provision For Income Taxes |  |  |
| Fedral tax expense | (668) | - |
| State tax expense | (1,600) | (800) |
| Net Income (loss) | (87,819) | (3,195) |
| Retained (deficit), Beginning Balance | (80,057) | (76,862) |
| Retained earnings (deficit), Ending Balance | $(167,876) | $(80,057) |

See independent auditors' report and accompanying notes to the financial statements.

- 6 -

# MEDFIRE INNOVATIONS, INC.  
STATEMENTS OF CASH FLOWS  
FOR THE YEARS ENDED DECEMBER 31, 2021 AND 2020

|  | 2021 | (Restated) 2020 |
| --- | --- | --- |
| Cash Flows From Operating Activities: |  |  |
| Net income (loss) | $(87,819) | $(3,195) |
| Adjustments to reconcile net profit to net cash provided by operating activities: |  |  |
| Depreciation and amortization | 2,974 | 2,773 |
| Change in operating assets and liabilities: |  |  |
| Inventory | 0 | 0 |
| Accounts payable | 0 | (8,644) |
| Sales tax payable | (15,006) | 15,006 |
| Credit cards payable | 16,561 | (8,199) |
| Net cash provided (used by) by operating activities | (83,290) | (2,259) |
| Cash Flows From Investing Activities: |  |  |
| Intangible asset purchases | (11,334) | (1,908) |
| Net cash provided by (used in) investing activities | (11,334) | (1,908) |
| Cash Flows From Financing Activities: |  |  |
| Accrued interest on shareholder loans | 4,030 | 4,611 |
| Payments on notes payable | 0 | (741) |
| Accrued interest on advances from related party | 3,443 | 0 |
| Payments on advances from related party | 0 | (465) |
| Issuance of preferred stock | 82,500 | 8,000 |
| Net cash provided (used) by financing activities | 89,973 | 11,405 |
| Net increase (decrease) in cash and cash equivalents | (4,651) | 7,238 |
| Cash and cash equivalents at beginning of year | 32,059 | 24,821 |
| Cash and cash equivalents at end of year | $27,408 | $32,059 |
| Supplemental Disclosures of Cash Flow Information: |  |  |
| Cash paid during the year for: |  |  |
| Income taxes | $1,468 | $800 |

See independent auditors' report and accompanying notes to the financial statements.

- 7 -

# MEDFIRE INNOVATIONS, INC.
NOTES TO THE FINANCIAL STATEMENTS
DECEMBER 31, 2021 AND 2020

# NOTE A - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

A summary of significant accounting policies of Medfire Innovations, Inc., a California corporation, (the "Company") is presented to assist in understanding the Company's financial statements. The financial statements and notes are representations of the Company's management who is responsible for their integrity and objectivity. These accounting policies conform to generally accepted accounting principles and have been consistently applied in the preparation of the financial statements.

# Business Activity

The Company was incorporated on June 22, 2016 under the laws of the State of California, and its principal business is the development and manufacture of new and innovative products that protect patients and patient care providers as well as development and manufacture of new and innovative products that make firefighting, rescue and police jobs easier and safer.

# Basis of Presentation

The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America.

# Cash and Cash Equivalents

The Company considers cash and cash equivalents to include demand deposits with financial institutions and highly liquid debt instruments with original maturities of 90 days or less when purchased.

# Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates.

# Revenue Recognition

In accordance with FASB Accounting Standards Codification ("ASC") 2014-09, Revenue from Contracts with Customers ("ASC 606") the Company recognizes the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. Revenue from contracts with customers consists of product sales revenue from Path-O Wrap and Path-O-Cap.

See independent auditors' report.

- 8 -

# MEDFIRE INNOVATIONS, INC.
NOTES TO THE FINANCIAL STATEMENTS
DECEMBER 31, 2021 AND 2020

NOTE A - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Cont.)

Revenue Recognition (Cont.)

Revenue is recognized when title passes to the buyer, generally upon shipment to the Company's customers.

The accounting records of the Company are maintained on the accrual basis. Accordingly, revenues are recorded in the period in which they are earned, and expenses are recorded in the period in which they are incurred. The effect of events on the business is recognized as services are rendered or consumed rather than when cash is received or paid.

The accounting records are maintained using the accrual method for financial reporting and income tax reporting purposes.

Inventories

Inventories are valued at the lower of cost or market on the first in first out (FIFO) method.

Intangible Assets

Intangible assets with finite lives are amortized on a straight-line basis over their estimated useful lives. Amortization expense was $2,974 and $2,773, respectively, for the years ending December 31, 2021 and 2020.

Impairment of Long-Lived Assets

In accordance with SFAS No. 144, Accounting for the Impairment or Disposal of Long-Lived Assets, the Company periodically reviews the recoverability of the carrying value of long-lived assets for impairment whenever events or circumstances indicate that their carrying value may not be recoverable. Recoverability of the assets is determined by analysis of the assets' fair value comparing the forecasted future undiscounted cash flows from operations to which the assets relate. If the carrying value is determined not be recoverable from future operating cash flows, the assets are deemed impaired and an impairment loss is recognized equal to the amount by which the carrying amount exceeds the estimated fair value of the assets. No such impairment was recorded for the years ended December 31, 2021 and 2020.

Advertising, Marketing, and Promotion Costs

The Company expenses advertising, marketing, and promotion costs as incurred.

See independent auditors' report.

- 9 -

# MEDFIRE INNOVATIONS, INC.
NOTES TO THE FINANCIAL STATEMENTS
DECEMBER 31, 2021 AND 2020

NOTE A - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Cont.)

Shipping and Handling Costs

The Company expenses shipping and handling costs as incurred as part of the cost of goods sold. Freight revenue has been reported as a reduction in cost of goods sold.

Research and Development

The Company is actively engaged in new product development efforts. Research and development expense related to possible future products are expensed as incurred. Total expense was approximately $0 and $500 for 2021 and 2020, respectively.

Income Taxes

Incorporated in the state of California and operating as a "C" corporation, the Company accounts for income taxes in accordance with FASB ASC 306-1-35, Accounting for Income Taxes.

The Company files income tax returns in the U.S. federal jurisdiction and the California, state jurisdiction. The Company is no longer subject to U.S. federal, state and local income tax examinations by tax authorities for years before 2018.

Concentration of Credit Risk

The Company performs ongoing credit evaluations of its customers and generally does not require collateral. As of December 31, 2021 and 2020, the Company has determined that an allowance is not necessary at his time.

Financial instruments that potentially subject the Company to credit risk principally consist of cash and cash equivalents and accounts receivable contracts. The Company grants unsecured credit to its customers.

The Company, at times during operations, has bank account balances which exceed $250,000. The Federal Deposit Insurance Corporation (FDIC) insures only $250,000 of funds. The Company has not experienced any losses in such accounts. Management believes that the Company is not exposed to any significant credit risk as to cash and cash equivalents. At December 31, 2021 and 2020 the Company had no uninsured cash balances.

See independent auditors' report.

- 10 -

# MEDFIRE INNOVATIONS, INC.
NOTES TO THE FINANCIAL STATEMENTS
DECEMBER 31, 2021 AND 2020

NOTE A - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Cont.)

Fair Value of Financial Instruments

The Company has adopted the provisions of FASB ASC 820-10 which provides a framework for measuring fair value under GAAP. It defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. It requires that valuation techniques maximize the use of observable inputs and minimize the use of unobservable inputs. It also establishes a fair value hierarchy, which prioritizes the valuation inputs into three broad levels.

There are three general valuation techniques that may be used to measure fair value, as described below:

A) Market approach - Uses prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities. Prices may be indicated by pricing guides, sale transactions, market trades, or other sources;
B) Cost approach - Based on the amount that currently would be required to replace the service capacity of an asset (replacement cost); and
C) Income approach - Uses valuation techniques to convert future amounts to a single present amount based on current market expectations about the future amounts (includes present value techniques, and option-pricing models). Net present value is an income approach where a stream of expected cash flows is discounted at an appropriate market interest rate.

The following methods and assumptions were used to estimate the fair value of each class of financial instruments for which it is practical to estimate that value:

Cash and Cash Equivalents and Inventories. The carrying amount is a reasonable estimate which approximates fair value.

Accounts Receivable. The carrying value of accounts receivable approximates the fair value due to the short-term nature of these instruments.

Notes payable & Shareholder Loan. The carrying amount is a reasonable estimate of fair value as interest rates and interest rates on long-term borrowings have not changed significantly from interest rates for similar loans at December 31, 2021 and 2020.

See independent auditors' report.

- 11 -

# MEDFIRE INNOVATIONS, INC.
NOTES TO THE FINANCIAL STATEMENTS
DECEMBER 31, 2021 AND 2020

# Recent Accounting Pronouncements

In February 2016, the FASB issued ASU 2016-02, Leases ("ASU 2016-02"). ASU 2016-02 requires a lessee to recognize a lease asset representing its right to use the underlying asset for the lease term, and a lease liability for the payments to be made to lessor, on its balance sheet for all operating lease greater than 12 months. ASU 2016-02 will be effective for fiscal years and interim periods within those fiscal years, beginning after December 2021 for the Company. The adoption of this standard is not expected to have a material impact on the Company's financial statements.

# NOTE B -CONVERTIBLE REDEEMABLE PREFERRED STOCK

On October 30, 2020, the Company issued 800 shares of Series A redeemable convertible preferred stock at $10.00 per share for total cash proceeds of $8,000.

During 2021 the Company issued 8,250 shares of Series A redeemable convertible preferred stock at $10.00 per share for total cash proceeds of $82,500.

# Conversion

At any time after January 1, 2027, each share of Series A redeemable convertible preferred stock, at the option of the holder, is convertible into an equal share of fully paid and nonassessable share of Common Stock, subject to the availability of authorized but unissued shares of Common Stock.

# Dividends

The holders of the Series A redeemable convertible preferred stock are entitled to receive dividends when and if declared by the Board of Directors at the annual Dividend Rate for the Series A preferred stock. The Dividend Rate is six percent (6%) of the Original Issue Price, or sixty cents ($0.60) per share per annum. Dividends on preferred stock are in preference to and prior to any payment of any dividend on common stock and are cumulative. As of December 31, 2021 and 2020, no dividends had been declared.

# Redemption

On or after January 21, 2027, the Company, at the written election of any holder of the Series A redeemable convertible preferred stock, is required to redeem, no later than sixty days after receiving the written notification, all or any portion of the shares of Series A redeemable convertible preferred stock held by such holder at a redemption price of $10.00 (the Original Issue Price) per share plus all declared and unpaid dividends thereon. If the Company does not have sufficient funds to redeem the requested shares, it may elect to pay in the form of a promissory note. The note shall bear interest at 5% with a term of no longer than two years.

See independent auditors' report.

- 12 -

# MEDFIRE INNOVATIONS, INC.
NOTES TO THE FINANCIAL STATEMENTS
DECEMBER 31, 2021 AND 2020

NOTE B -CONVERTIBLE REDEEMABLE PREFERRED STOCK(Continued)

Redemption (continued)

On or after January 1, 2030, the Company may, at the option of the Board of Directors, redeem in whole or in part shares of the Series A redeemable convertible preferred stock held by all or any number of selected holders such stock. The Company must provide written notice sixty days in advance of the redemption to the stockholder.

Liquidation preference

In the event of any liquidation, dissolution or winding up of the Company, the holders of the Series A redeemable convertible preferred stock are entitled to receive prior to, and in preference to, any distribution to the common stockholders, an amount per share equal to the Original Issue Price ($10.00 per share) plus accrued but unpaid dividends. In the event that upon liquidation or dissolution, the assets and funds of the Company are insufficient to permit the payment to preferred stockholders of the full preferential amounts, then the entire assets and funds of the Company legally available for distribution are to be distributed ratably among the holders of the shares of Series A redeemable convertible preferred stock in proportion to the number of outstanding shares of Series A redeemable convertible preferred stock held by each stockholder.

After the distributions described above have been paid in full, the remaining assets of the Company available for distribution shall be distributed pro-rata to the holders of the shares of common stock.

Voting rights

The Series A redeemable convertible preferred stock is non-voting.

NOTE C -RELATED PARTY NOTES PAYABLE/DUE TO RELATED PARTY

On March 1, 2020 the Company issued a note payable in the amount of $26,000 to the related party, Marshall Lane Surprise, LLC to consolidate the previously issued notes. The consolidated note has interest at 5% with all unpaid principal and interest due on maturity, March 1, 2025.

Due to related party consists of expenses paid by Marshall Lane Surprise, LLC and by the shareholder for the Company. The balance at December 31, 2021 and 2020 was $1,732.

See independent auditors' report.

- 13 -

# MEDFIRE INNOVATIONS, INC.
NOTES TO THE FINANCIAL STATEMENTS
DECEMBER 31, 2021 AND 2020

NOTE C -RELATED PARTY NOTES PAYABLE/DUE TO RELATED PARTY (Continued)

| Notes payable related party consists of the following: |  |  |
| --- | --- | --- |
|  | 2021 | 2020 |
| Marshall Lane Surprise, LLC; interest at 5%; all principal and interest due on maturity March 1, 2025. | 26,000 | 26,000 |
| Accrued interest | 4,434 | 991 |
| Total notes payable | 30,434 | 26,991 |
| Less current portion | 0 | 0 |
| Notes payable - long term | $30,434 | $26,991 |

NOTE D - SHAREHOLDER LOANS

On February 24, 2020 the Company issued a note payable in the amount of $64,000 to the shareholder to consolidate the previously issued notes to shareholder. The consolidated note has interest at 5% with all unpaid principal and interest due on maturity, March 1, 2025. The balance due on this note including accrued interest at December 31, 2021 and 2020 was $69,596 and $65,566, respectively.

NOTE E - COMMITMENTS AND CONTINGENCIES

Operating Lease

In September 2019, the Company entered into a lease agreement for office space. The lease expires October 31, 2023. Initial rent has been deferred until September 1, 2021. Initial rent is $1,200 per month increasing to $1,800 per month on March 21, 2021. On February 8, 2021 the office space lease was amended to defer the start date of payments to January 15, 2022. The amendment also added a one-time additional payment of $1,000 to be paid with the rent on that date.

Future minimum rental payments required under the amended lease that has an initial or remaining lease term in excess of one year are as follows at December 31:

| 2022 | $22,600 |
| --- | --- |
| 2023 | 5,400 |
| 2024 | 0 |
| 2025 | 0 |
| 2026 | 0 |
| Thereafter | 0 |
|  | $28,000 |

See independent auditors' report.

- 14 -

# MEDFIRE INNOVATIONS, INC.
NOTES TO THE FINANCIAL STATEMENTS
DECEMBER 31, 2021 AND 2020

# NOTE E - COMMITMENTS AND CONTINGENCIES (Continued)

In September 2019, the Company entered into a lease agreement for storage space. Rent has been deferred on this lease until February 1, 2022. The lease a month-to-month lease with initial rent at $300 per month increasing to $450 per month after the first six months.

# NOTE G - RESTATEMENT

The Company has discovered that previously issued financial statements included stock offering costs misclassified as intangible assets. The misclassification resulted in differences in previously issued financial statements sufficient to require restatement of the previously issued annual financial statements.

The following sets forth previously reported and restated amounts of selected within the balance sheets as of December 31, 2020 and within the statements of income and cash flows for the years then ended:

| Selected Balance Sheet Data as of December 31, 2020 |  | As previously reported | As Restated |
| --- | --- | --- | --- |
| Current liabilities |  |  |  |
|  | Sales tax payable | $0 | $15,006 |
|  | Retained (deficit) | (65,051) | (80,057) |
| Selected Statement of Income Data as of December 31, 2020 |  |  |  |
|  | Revenue | $202,074 | $187,068 |
|  | Net Income (loss) | 11,811 | (3,195) |
| Selected Statement of Cash Flow Data as of December 31, 2020 |  |  |  |
|  | Net Income | $11,811 | $(3,195) |
|  | Sales tax payable | 0 | 15,006 |

# NOTE F - DATE OF MANAGEMENT EVALUATION

Management has evaluated subsequent events for recognition and disclosure through February 21, 2022, the date on which the financial statements were available to be issued.

See independent auditors' report.

- 15 -

**Attachment 6:** `emedpossible.pdf`

# Exhibit D Possible Future Operations of MedFire

## Possible Future Operations

MedFire plans to continue to develop, manufacture, and sell products and services it has created under MedFire Innovations or via its collaboratives with select organizations, groups, or other individuals. We also intend to be a profitable company and will try to achieve growth year over year for our company employees and shareholders by expanding future operations while continuously growing our primary target markets. As Company growth and revenues enable such expansion, MedFire also intends to develop a philanthropic arm of the Company. The following areas are on our intended roadmap for expansion: MedFire Labs and the MedFire Educational Center.

We envision future expansion of our company by expanding in various areas, while at the same time, staying focused on our primary target markets. As MedFire grows and increases revenues allowing for future expansion, MedFire intends to use some future proceeds to expand by developing both for profit divisions and increase our philanthropy. The following areas will be our intended roadmap for expansion: MedFire Labs, and the MedFire Educational Center.

## MedFire Labs

The Company intends to move forward soon with an additional division - MedFire Labs. This division is being created to facilitate the need to provide supplements and other products to our target audiences, including resources for fitness and health. We will provide end-user customers with premium, lab-tested, supplements formulated specifically for the high-performance our customers need to stay in top physical condition, both physically and mentally. MedFire Labs supplements will be made in the USA in FDA Registered facilities. This division will provide our customers with top resources boasting the latest information on these topics.

## MedFire Educational Center

MedFire envisions a world of possibility. We may use some of our future profits to develop and maintain a place for our younger generation to be creative, learn, develop, and ultimately, feel safe. The MedFire Center(s) can be this place. These centers would provide free, hands-on learning, lectures on life and business, creative collectives, and a safe place to spend time. The Centers could allow younger people opportunities for mentorship or other collaborations with professionals who have already established themselves in the sciences, medicine, nursing, fire and rescue, and in product development for these industries. The goal of MedFire Educational Center is to create a Center that achieves immediate and lasting change in the lives of those who attend, instilling confidence, supporting success, promoting kindness, and empowering a future ability to *pay it forward*.

## Social Impact

MedFire was founded to impact communities through innovation. To further this impact and pay our success forward, we plan to use some of our profits to help those who want to help other as defined in our Vision and Mission. We intend to use up to 10% of our annual net profits, as determined by our Board of Directors to be in the best interests of the Company, to provide funding to innovators with new ideas that would improve the safety and capabilities of those who work directly in the medical, public safety, and emergency service professions.

MedFire’s funds will be strategically deployed to help build a healthy social enterprise ecosystem, with a penchant for self-sustaining, scalable entities beyond the traditional charitable model. These funds may take the form of loans, equity investments, grants, or other financial vehicles, as determined in the best interests of our Board of Directors. We are passionate about assisting those with great ideas that will make a real impact on our target industries, and we feel that there are some groups that are currently under-represented when it comes to making great ideas happen. In our commitments to economic empowerment and diversity and inclusion or creators in the product innovation space, we want to provide this funding to individuals and groups that may lack resources and opportunities to bring these ideas to light. We aim to empower a diverse population of young people; by supporting inventive minds of all backgrounds and ethnicities working in our target industries, we aim to bolster the work of those who may not otherwise have access to the tools, resources and expertise to further their inventions. By supporting new innovators, we hope to add yet another layer to the various ways in which MedFire improves access to the best products and services to help those who are in the business of helping others.

**Attachment 7:** `fmedsubagree.pdf`

# MEDFIRE INNOVATIONS INC.

# SUBSCRIPTION AGREEMENT

THIS SUBSCRIPTION AGREEMENT ("Agreement") is made as of ______________, (the "Effective Date") by and between Medfire Innovations Inc., a California corporation (the "Company"), and ________________________ ("Subscriber").

1. SUBSCRIPTION. In consideration for Subscriber paying $____.00 to Company, Company hereby issues to Subscriber shares of Preferred Stock in Company (the "Shares"), based on a price of $10 per share, on the terms set forth in Company's Articles of Incorporation, in this Agreement, and on the Crowdfund Mainstreet (MiTec, PBC) regulation crowdfunding platform.
2. REPRESENTATIONS AND WARRANTY OF COMPANY. Company hereby represents and warrants to each Subscriber as follows:

2.1 Organization, Good Standing and Qualification. Company is a corporation duly organized, validly existing, and in good standing under the laws of the State of California. Company has all requisite corporate power and authority to execute and deliver this Agreement, to issue and sell the Shares, to carry out the provisions of this Agreement, and to own and operate its properties and assets and carry on its business as presently conducted.
2.2 Authorization; Binding Obligations. All corporate action on the part of Company as necessary for the authorization of this Agreement, the performance of all obligations of Company hereunder, and the authorization, sale, issuance, and delivery of the Shares pursuant hereto has been taken. This Agreement, when executed and delivered, will be a valid and binding obligation of the Company enforceable in accordance with its terms, except (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium, or other laws of general application affecting enforcement of creditors' rights and (ii) as limited by general principles of equity that restrict the availability of equitable remedies.
2.3 Governmental Consents and Filings. No consent, approval, order, or authorization of, or registration, qualification, designation, declaration, or filing with, any federal, state, or local governmental authority is required on the part of Company in connection with the consummation of the transactions contemplated by this Agreement, except for state and federal securities filings required in connection with an offering under Regulation Crowdfunding.
2.4 Articles of Incorporation. A true and complete copy of Company's Articles of Incorporation in effect at the time of Company's execution of this Agreement is attached hereto as Exhibit A.
3. REPRESENTATIONS, WARRANTY AND COVENANTS OF SUBSCRIBER. Subscriber hereby represents, warrants, and covenants to Company as follows:
3.1 Company May Rely on These Representations. Subscriber understands that Company's offer and sale of the Shares has not been registered under the Securities Act of 1933, as amended (the "1933 Act"), because Company believes, relying in part on Subscriber's representations in this Agreement, that an exemption from such registration requirement is

1

available for such sale. Subscriber understands that the availability of this exemption depends in part upon the representations Subscriber is making to Company in this Agreement being true and correct.

**3.2 No Resale for One Year.** Subscriber understands that the Shares may not be resold for one year after the date of issuance (with limited exceptions) and that even after one year resale may require additional securities compliance and there may not be any market for the Shares.

**3.3 No Resale Without Registration or Exemption.** Subscriber has been advised that the Shares have not been registered under the Securities Act, or any state securities laws and, therefore, cannot be resold unless they are registered under the Securities Act and applicable state securities laws or unless an exemption from such registration requirements is available.

**3.4 Subscriber Can Protect Its Interests.** Subscriber understands that the purchase of the Shares involves a high degree of risk, and that Company's future prospects are uncertain. Subscriber understands the risks involved in the purchase of the Shares, including (1) the speculative high-risk nature of the investment; (2) the financial hazards involved, including the risk of losing the entire investment; and (3) the lack of liquidity of the investment due to the absence of a trading market for the Shares. Subscriber has fully reviewed Company's information on the Crowdfund Mainstreet platform, including Company's Form C and all amendments thereto, if any. Subscriber has such knowledge and experience in financial and business matters that Subscriber can properly evaluate the merits and risks of purchase of the Shares and can protect Subscriber's own interests in this regard.

**3.5 Subscriber Advised to Seek Representation.** Subscriber understands that nothing in this Agreement or any other materials presented to Subscriber in connection with the purchase and sale of the Shares constitutes legal, tax, or investment advice. Company has advised Subscriber to consult with such legal, tax, and investment advisors as Subscriber, in its sole discretion, deems necessary or appropriate in connection with its purchase of the Shares.

**3.6 Information.** Subscriber acknowledges that it has received all the information it has requested from Company and it considers necessary or appropriate for deciding whether to acquire the Shares. Subscriber represents that it has had an opportunity to ask questions and receive answers from Company regarding the terms and conditions of the offering of the Shares and to obtain any additional information necessary to verify the accuracy of the information given to Subscriber.

**3.7 Indemnity.** Subscriber agrees to indemnify and hold harmless Company and its officers and directors for any claims, judgments, or expenses incurred as a result of any misrepresentation made by Subscriber.

**3.8 Authority; Binding Agreement.** Subscriber represents and warrants to, and covenants with, Company that (i) Subscriber has full right, power, authority, and capacity to enter into this Agreement and to consummate the transactions contemplated hereby and has taken all necessary action to authorize the execution, delivery, and performance of this Agreement, and (ii) this Agreement constitutes a valid and binding obligation of Subscriber enforceable against Subscriber in accordance with its terms, except as enforceability may be limited by applicable law.

2

3.9 **Further Assurances.** Subscriber agrees and covenants that at any time and from time to time it will promptly execute and deliver to Company such further instruments and documents and take such further action as Company may reasonably require in order to carry out the full intent and purpose of this Agreement.

3.10 **Complete Information.** All information provided by Subscriber to Company herein, and all information provided by Subscriber to Company in connection with the purchase and sale of the Shares, is true, correct, and complete as of the date hereof, and if there should be any change in such information, Subscriber will immediately provide Company with such information.

#### 4. MISCELLANEOUS.

4.1 **Binding Agreement.** The terms and conditions of this Agreement shall inure to the benefit of and be binding upon the respective successors and assigns of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any third party any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement.

4.2 **Governing Law.** This Agreement shall be governed by and construed under the laws of the State of California.

4.3 **Counterparts.** This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

4.4 **Titles and Subtitles.** The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement.

4.5 **Notice.** Any notice or demand which either party may or must give to the other under this Agreement shall be made in writing and shall be either hand delivered or sent via email or U.S. certified mail to the following addresses, or at such other addresses which each party may later designate in writing to the other party:

# *If to Company:*

Medfire Innovations Inc.  
2425 Camino Del Rio South, Suite 125  
San Diego, CA 92108

**Phone Number: 888-560-1140**

3

# *If to Subscriber: at the address provided via the Crowdfund Mainstreet platform.*

4.6 **Severability.** In the event that any provision of this Agreement becomes or is declared by a court of competent jurisdiction to be illegal, unenforceable, or void, this Agreement shall continue in full force and effect without said provision; provided that no severance shall be effective if it materially changes the economic benefit of this Agreement to any party.

4.7 **Entire Agreement.** This Agreement, along with the agreements completed on the Crowdfund Mainstreet platform, constitutes the final, complete, and exclusive statement of the terms of the agreement between the parties pertaining to Subscriber’s purchase of the Shares from Company and supersedes all prior and contemporaneous understandings or agreements of the parties.

4.8 **Amendments.** Any term of this Agreement may be amended either retroactively or prospectively, with the written consent of Company and Subscriber. All amendments shall be effective only when in writing signed by the parties.

4.9 **Expenses.** Company and Subscriber shall each be responsible for bearing their own expenses incurred on their behalf (including attorney’s fees) with respect to this Agreement and the transaction contemplated hereby.

4.10 **Company’s Right to Accept or Reject Investments.** Company may accept or reject any investments, in whole or in part. This means that Company may sell to Subscriber a smaller number of Shares than Subscriber subscribes to purchase or may choose not to sell Shares to Subscriber. If Company accepts Subscriber’s investment, in whole or in part, except as otherwise set forth on the Crowdfund Mainstreet platform, this Agreement will constitute an irrevocable commitment by Subscriber to purchase the Shares, and a copy of this Agreement will be executed by Company and returned to Subscriber. If Company rejects Subscriber’s investment in whole or in part, Company will return the payment tendered for any unissued portion of the investment.

4.11 **Tax Withholding.** Subscriber hereby authorizes Company to make any withholding required by law. Subscriber agrees to provide to Company a Form W-9 or comparable form.

4.12 **Electronic Signatures.** Each party to this Agreement agrees that electronic signatures, whether digital or encrypted, to this Agreement are intended to authenticate this writing and to have the same force and effect as manual signatures. Electronic signature means any electronic sound, symbol, or process attached to or logically associated with a record and executed and adopted by a party with the intent to sign such record, including facsimile or email electronic signatures.

[THE REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK]

4

- -

IN WITNESS WHEREOF, the parties have executed this SUBSCRIPTION AGREEMENT as of the date first written above.

COMPANY:

Medfire Innovations Inc.
a California corporation

By:_________________________

Name: Gregory Christmas

Title: CEO

**SUBSCRIBER:**

**IF SUBSCRIBER IS AN INDIVIDUAL:**

PRINT NAME

SIGNATURE

**SUBSCRIBER:**

**IF SUBSCRIBER IS AN ENTITY:**

PRINT NAME OF ENTITY

By:

(Signature)

(Print Name)

Its:

(Print Title)

# EXHIBIT A

# **Articles of Incorporation**

**Attachment 8:** `gmedcampaign.pdf`

MedFire Campaign Page

CROWDFUND
mainstreet

🔍

Contact

Learn

Closed Campaigns

Raise Funds

🔍

# MedFire Innovations, Inc.

California United States

## We've Done The Work, And It Shows.

MedFire is dedicated to advancing the products, strategies and personal connections required to positively impact the healthcare and public safety community. The company is comprised of MedFire Innovations and MedFire Jobs & Expo. Founded by healthcare professionals and public safety first - responders, we understand what solutions will have lasting impact, and know how to get them to the finish line.

![img-0.jpeg](img-0.jpeg)

Help

CROWDFUND
mainstreet

🔍

Contact

Learn

Closed Campaigns

Raise Funds

📄

![img-1.jpeg](img-1.jpeg)

#Community #Bio-Tech #Health #Services

$0 FUNDS RECEIVED
of $1,000,000 maximum target

$50K MINIMUM

# Investment Summary

Preferred Stock

Minimum Investment: $500.00

Dividend: 6%

*See Offering section below for disclosures

Help

CROWDFUND
mainstreet

Contact

Learn

Closed Campaigns

Raise Funds

# Offering

## Equity

- MedFire Executive Team (2023).pdf
- MEDFIRE Pitch Deck 2023.pdf
- Use of Proceeds.pdf
- MedFire - Possible Future Operations of MedFire (1).pdf

## Mission

![img-2.jpeg](img-2.jpeg)

"Serving Those In The Business Of Serving Others"

Help

CROWDFUND
mainstreet

Contact

Learn

Closed Campaigns

Raise Funds

MedFire Innovations is taking a targeted approach to health and community care by developing and launching products that strategically improve the lives of patients and providers. From common patient concerns to what healthcare workers need to protect themselves or perform procedures successfully. Our products deliver the gamechangers: simpler solutions to large and pressing market problems.

For more than five years, we have combined deep industry knowledge with best-in-class practices. Our successes to date include:

- Path-O-Wrap: A patented products providing a protective barrier to pathogens between a person and a surface such as a hospital mattress:
- The Williams Key: A passive entry tool for first-responders to enter locked areas without causing damage.
- Recopad: A device that allows a caregiver to obtain a urine specimen from patients with dependencies or disabilities, without the discomfort or embarrassment of a catheter.
- Self-pap: (in development) A device enabling patients to obtain testing samples for life-threatening cervical cancer easily and discretely - in their own home, that could change cervical cancer screening on a global scale.

The healthcare market is growing and we are finding significant opportunities in the gaps of how care is currently delivered. Join us and support product innovation that will transform the healthcare landscape here and around the

Help

[LOGO]

CROWDFUND

mainstreet

Q

Contact

Learn

Closed Campaigns

Raise Funds

[LOGO]

The healthcare market is growing and we are finding significant opportunities in the gaps of how care is currently delivered. Join us and support product innovation that will transform the healthcare landscape here and around the world.

Invest with impact. Invest in MedFire, and let's make a difference together.

![img-3.jpeg](img-3.jpeg)

MedFire - Creating a Culture of Innovation

Help

CROWDFUND
mainstreet

Contact

Learn

Closed Campaigns

Raise Funds

## The MedFire Innovations Model: A Strategy That Works.

Creating a Culture of Innovation

MedFire Innovations began with a single idea. While creating our first product, Path-O-Wrap®, we experienced firsthand the immense value in developing key relationships and having access to strategic resources. We now offer that expert insight, access, and mentorship to those creating other products and devices that share our mission of positively impacting those who care for and protect others.

![img-4.jpeg](img-4.jpeg)

Help

Click to go back, hold to see history

Contact

Learn

Closed Campaigns

Raise Funds

![Home icon]()

![img-5.jpeg](img-5.jpeg)

Whether someone is a healthcare professional with an exciting invention they want to make a reality, or an experienced company looking to source better design, prototyping or manufacturing options, we connect readily with those who share our mission to serve those who serve our communities.

CROWDFUND
mainstreet

🔍

Contact

Learn

Closed Campaigns

Raise Funds

# MedFire Innovations In Action: Success Stories

![img-6.jpeg](img-6.jpeg)

Help

CROWDFUND
mainstreet

Contact

Learn

Closed Campaigns

Raise Funds

# WILLIAMS KEY

The Williams Key is an emergency (passive entry)
device used by First Responders to gain quick access
into buildings and houses. The purpose of the device
is to toggle the strike of a lock without doing damage
to the lock, door, or frame. It works well on gates with
anti-vandal plates, elevator control rooms, commercial
utility doors and many other outward swinging metal
and wood doors. This device was developed in
response to the need by first responders to gain access
to locked areas, without having to damage or destroy
property in the process of gaining emergency access.

![img-7.jpeg](img-7.jpeg)

The Williams Key

![img-8.jpeg](img-8.jpeg)

Help

[Non-Text]

CROWDFUND

mainstreet

Q

Contact

Learn

Closed Campaigns

Raise Funds

?

## recopad

The Recopad was designed for dependent patients; those patients with difficulties providing urine samples by themselves (i.e. elderly patients, physically disabled, and patients with any cognitive disease) who require constant urinalysis. The Recopad is a comfortable, non-invasive device able to collect a urine sample directly from a specially designed diaper, without filtering or altering the chemical composition, to perform a precise urine analysis.

![img-9.jpeg](img-9.jpeg)

The Recopad

### SELF-PAP FOR CERVICAL CANCER SAMPLING

The Self-Pap for cervical cancer sampling device was designed as a lower-cost, easy-to-use and effective device for women to collect samples necessary to identify this threatening cancer. This device was also developed for use in parts of the world where cultural barriers make such testing difficult if not impossible, and where medical treatment and clinics are limited, or they are geographically remote and difficult to access.

Help

CROWDFUND
mainstreet

Q

Contact

Learn

Closed Campaigns

Raise Funds

?

## Sparking The Right Connections Between People and Companies

The Intersection where Jobs and Careers meet the Companies who Embrace Them...

![img-0.jpeg](img-0.jpeg)

MedFire Jobs and Expo is a platform specifically serving the needs of job seekers and companies in the Healthcare, Science, Veterinary and Public Safety fields. Through the online network we have established, organizations and individuals can connect at key points in their quests to improve community care and safety.

MedFire Jobs and Expo is a thorough and interactive database, featuring:

- A RECRUITING DATABASE for companies to connect with top-tier candidates.

Help

CROWDFUND
mainstreet

Contact

Learn

Closed Campaigns

Raise Funds

- A JOB SEARCH PLATFORM for seekers to find great careers.
- AN EDUCATIONAL HUB for training and continuing education opportunities.
- A RESOURCE LIBRARY, with industry - related stories, blogs, podcasts, photo journals and more.
- A PLACE FOR PEER - TO - PEER CONNECTION and collaboration, sharing new information and research.
- A LAUNCHPAD where organizations market, advertise and demonstrate their products and services directly to their preferred audiences.

MedFire Jobs and Expo is GLOBAL - offering information and perspective, partners and opportunities in the United States and also throughout the world.

Join the growing MedFire community today.

![img-1.jpeg](img-1.jpeg)

Help

CROWDFUND
mainstreet

Q

Contact

Learn

Closed Campaigns

Raise Funds

# Investment Perks

$500

"Innovator"

The "Innovator" will receive a MedFire Innovations T-shirt and recognition on our "Founders" page on our company platforms. This is our Thank You for your contribution to our Company, and to Helping Those in The Business Of Helping Others.

$1,000

"Believer"

The "Believer" will receive everything in the "Innovator" section, plus Life-Time admission to any MedFire Jobs & Expo events, and Life-Time invitations to any MedFire Jobs & Expo receptions.

$7,500

"Game Changer"

The "Game Changers" will be entitled to everything in our "Innovator" and "Believer" sections, plus, a "Game Changer" will be entitled to Life-Time free advertising on our MedFire Jobs & Expo platforms. This offer is limited to only five (5) companies, organizations, or individuals, and is on a first-come, first serve basis.

CROWDFUND
mainstreet

Q

Contact

Learn

Closed Campaigns

Raise Funds

# Key Facts & Financials

○ MedFire Innovations is a California based company. C-Corporation. Incorporated in 2016
○ MedFire Innovations is an FDA Registered company.
○ MedFire holds 10 United States Patents, and 2 Registered Trademarks.
○ MedFire Innovations develops products and devices for our company, and for individuals and organizations looking for assistance with device development.
○ Some of MedFire services include: Feasibility Studies; Concept Development; Design for Manufacturing; Prototype Production, and Verification and Validation Testing.
○ MedFire has multiple devices ready to sell

MedFire_Amended_Articles_of_Inc...

Audited Financials.pdf

Help

CROWDFUND
mainstreet

Contact

Learn

Closed Campaigns

Raise Funds

☐ MedFire has multiple devices ready to sell into the healthcare market, and exciting new devices currently in development, that we believe will have a great impact in women's healthcare.

☐ MedFire Jobs and Expo is ready to launch. This platform was developed for Healthcare Professionals and First-Responders. To provide a platform for career development, a thorough resource library, and an Expo to showcase products and services to the healthcare and public safety community.

CROWDFUND^{}[] mainstreet

Contact

Learn

Closed Campaigns

Raise Funds

# MedFire Innovations, Inc. Story

## *Company History*

MedFire Innovations was founded by Gregory Christmas and was formally incorporated in California in 2016. MedFire was established to develop simple products that would help protect patients and patient care providers, protecting those who work in the business of protecting others. After a long career in emergency services, Christmas realized that the development of simple and easy to use products that would assist in the day-to-day operations of those working on the front lines of emergency medical services could transform safety and personal experience - so it became MedFire’s original mission to encourage development of innovative products.

Christmas’ decision to launch MedFire was heavily influenced by his decades-long career in emergency services; he had been employed as a Fire Captain - Paramedic, and during the routine processes of repetitively cleaning equipment used in the field to aid in the treatment of patients, Greg Christmas realized there was a need to provide a clean barrier between the equipment and the patients and provider. Such a barrier would reduce exposure to harmful pathogens. The challenge was to come up with a simple and effective method to provide this protective surface barrier. From that challenge, and the

![Help icon]() Help

[LOGO]

CROWDFUND
mainstreet

Q

Contact

Learn

Closed Campaigns

Raise Funds

e

successful development of that device to answer that call, MedFire Innovations was born.

The development and successful patenting of our first product, our protective barrier device, Path-O-Wrap® required us to develop a successful business process from ideation to execution that we formalized into an organization (MedFire Innovations) offering that support and structure to fellow innovators. Parent company MedFire Innovations rapidly expanded to the three divisions we have today: MedFire Innovations, providing and supporting the development of market-driven products and services to medical, health, public safety, and other care environments; MedFire Jobs, an online hiring platform; and MedFire Expo, and online business marketplace to support the networking and growth of companies developing products and services withing this sector.

Born From a Single Idea...

MedFire Innovations was born from a single idea: After creating our first product, we experienced firsthand the immense value in developing key relationships and having access to strategic resources. We originally began by developing, manufacturing, and bringing to market our own innovative ideas in the form of additional products and services, then expanded our services to include helping other innovators in our market space to create their own products and devices through a custom collaboration process. MedFire has gone from our single product idea into a company that multiplied that successful business model, rapidly expanding into a diverse company focused

https://crowdfundmainstreet.com

Help

CROWDFUND^{}[] mainstreet

Contact

Learn

Closed Campaigns

Raise Funds

on serving those who provide for - and protect others.

MedFire Innovations is comprised of various divisions focused on developing products, devices, and services for our company and for others. The three distinct divisions of MedFire are all tied together by a commitment to *Help Those Who Are In The Business Of Helping Others*. MedFire has cultivated a vast network of creative and innovative experts to help develop great ideas move from concept to tactical reality. We have created a Culture of Innovation by sharing ideas and concepts within this network of biomedical, mechanical, and electrical engineers; manufacturers; packaging experts; technical and regulatory specialists; sales and marketing professionals; and other key experts, all with one goal in mind - To Bring Innovations To Life.

## The Founders

### Gregory Christmas

President & Founder

![img-2.jpeg](img-2.jpeg)

Gregory Christmas founded MedFire Innovations and serves the Company as the President and Chairman of the Board of Directors. He is an experienced entrepreneur with a background in private sector business and public service in emergency operations, and administrative management. Prior to the founding of the company, Mr. Christmas has extensive 30+ years of experience working in the Public Safety industry, including as a Fire Captain - Paramedic in California. He was awarded the Public Safety Award by his City and Fire Department in 2008 for life-saving action. Mr. Christmas holds a Bachelor of Science Degree in Business

Help

C

CROWDFUND

mainstreet

Q

Contact

Learn

Closed Campaigns

Raise Funds

#

# Gregory Christmas

# President & Founder

![img-3.jpeg](img-3.jpeg)

Gregory Christmas founded MedFire Innovations and serves the Company as the President and Chairman of the Board of Directors. He is an experienced entrepreneur with a background in private sector business and public service in emergency operations, and administrative management. Prior to the founding of the company, Mr. Christmas has extensive 30+ years of experience working in the Public Safety industry, including as a Fire Captain - Paramedic in California. He was awarded the Public Safety Award by his City and Fire Department in 2008 for life-saving action. Mr. Christmas holds a Bachelor of Science Degree in Business Administration and a Master of Public Administration.

# The Team

# Staci Mehl

Vice President - Sales Development

Staci Mehl is Vice President of Sales Development for MedFire Innovations. She has served on the Board of Directors of MedFire since 2019 and is a Director of the company. Staci has worked with MedFire as an independent consultant to MedFire since 2016. Staci is responsible for the development of product sales for the Company. Staci holds a Bachelor's Degree in Microbiology from Texas A&M University.

# Andrea Siller

Consultant - Bio Engineer

Andrea Siller is our Chief Biomedical Engineer, and regulatory consultant. Andrea is passionate about helping to improve the lives of people by applying her talents and skills in design engineering. She is extremely experienced in product design and development processes, project planning and management, quality control and regulatory compliance, and business development. Andrea won the National Entrepreneur Award (Mexico) in 2017, has been a moderator on FORBES Health Panels, has a TEDx Talk, and was recognized by Vogue UK Magazine and One Young World as part of the "Game Changers" generation.

www.medfire.com

Help

**Attachment 9:** `hmedamendedart.pdf`

A0835033

3120108

AMENDED AND RESTATED
ARTICLES OF INCORPORATION

FILED
Secretary of State
State of California
OCT 22 2019

# MEDFIRE INNOVATIONS INC.

The undersigned certifies that:

A. He is the president and secretary of MedFire Innovations Inc., a California corporation (the "Corporation").

B. The Articles of Incorporation of the Corporation are amended and restated to read in full as follows:

# ARTICLE I:

# NAME

The name of the Corporation is MedFire Innovations Inc.

# ARTICLE II:

# PURPOSE

The purpose of the Corporation is to engage in any lawful act or activity for which a corporation may be organized under the General Corporation Law of California other than the banking business, the trust company business or the practice of a profession permitted to be incorporated by the California Corporations Code.

# ARTICLE III:

# AUTHORIZED STOCK

This Corporation is authorized to issue two classes of stock to be designated, respectively, "Common Stock" and "Preferred Stock." The total number of shares which the Corporation is authorized to issue is two million five hundred thousand (2,500,000) shares; two million (2,000,000) shares of which shall be Common Stock (the "Common Stock"), and five hundred thousand (500,000) shares of which shall be Preferred Stock (the "Preferred Stock"). The Preferred Stock and the Common Stock shall each have a par value of one ten-thousandth of a dollar ($0.0001) per share. All of the five hundred thousand (500,000) shares of Preferred Stock are hereby designated "Series A Preferred Stock" (the "Series A Preferred").

# ARTICLE IV:

# RIGHTS, PREFERENCES AND PRIVILEGES OF STOCK

The rights, preferences, privileges, restrictions granted to and imposed on, and other matters relating to, the Series A Preferred and the Common Stock are as follows:

MedFire Innovations Inc.

1

Amended and Restated Articles of Incorporation

A0835033

1. DEFINITIONS. For the purposes of this Article IV, the following definitions apply:

1.1 "Board" shall mean the Board of Directors of the Corporation.
1.2 "Common Stock Dividend" shall mean a stock dividend declared and paid on the Common Stock that is payable in shares of Common Stock.
1.3 "Dividend Rate" shall mean six percent (6%) of the Original Issue Price, or sixty cents ($0.60) per share per annum for the Series A Preferred (as adjusted for any future stock dividends, combinations, splits recapitalizations and the like with respect to such shares).
1.4 "Original Issue Date" shall mean the date on which the first share of Series A Preferred is issued by the Corporation.
1.5 "Original Issue Price" shall mean Ten Dollars ($10.00) per share for the Series A Preferred. Each Original Issue Price shall be as adjusted for any future stock splits, stock dividends, recapitalizations or the like, with respect to the Series A Preferred.

# 2. DIVIDEND RIGHTS.

2.1 Series A Preferred. The holders of the then outstanding Series A Preferred shall be entitled to receive, when, as and if declared by the Board, out of any funds and assets of the Corporation legally available therefor, cumulative dividends at the annual Dividend Rate for the Series A Preferred, prior and in preference to the payment of any dividend on the Common Stock (other than a Common Stock Dividend). Such dividends shall accrue on each share of Series A Preferred from the date on which such share of Series A Preferred is issued by the Corporation, and shall accrue from day to day until paid, whether or not earned or declared. No accumulation of dividends on the Series A Preferred shall bear any interest. To the extent that dividends are not declared by the Board, they will continue to accrue, but no payments upon such accrued and undeclared dividends will be due to holders of Series A Preferred, subject to Section 3 and 4 below. The Board has sole discretion as to if and/or when dividends may be declared, or not, subject to any requirements of the California Corporations Code. Unless the full amount of any accrued and unpaid cumulative dividends accrued on the Series A Preferred shall have been paid or declared in full and a sum sufficient for the payment thereof reserved and set apart, no dividend (other than a Common Stock Dividend) shall be paid or declared on any Common Stock.

2.2 No Participation Rights. If, after dividends in the full preferential amounts specified in this Section 2 for the Series A Preferred have been paid or declared and set apart in any calendar year of the Corporation, the Board shall declare additional dividends out of funds legally available therefor in that calendar year, then such additional dividends shall be declared solely on the Common Stock.

3. LIQUIDATION RIGHTS. In the event of any liquidation, dissolution or winding up of the Corporation, whether voluntary or involuntary, the funds and assets that may be

MedFire Innovations Inc.

2

Amended and Restated Articles of Incorporation

A0835033

legally distributed to the Corporation's shareholders (the "Available Funds and Assets") shall be distributed to shareholders in the following manner:

3.1 Series A Preferred. The holder of each share of Series A Preferred then outstanding shall be entitled to be paid, out of the Available Funds and Assets (and prior and in preference to any payment or distribution setting apart of any payment or distribution of any Available Funds and Assets on Shares of Common Stock), an amount per share equal to the Original Issue Price of the Series A Preferred plus all accrued and unpaid dividends thereon, to and including the date full payment of such amount shall be tendered to the holders of the Series A Preferred with respect to such liquidation, dissolution or winding up (the "Preference Amount"). If upon any liquidation, dissolution or winding up of the Corporation, the Available Funds and Assets to be distributed to the holders of the Series A Preferred shall be insufficient to permit the payment to such shareholders of their full preferential amount described in this subsection, then all of the Available Funds and Assets shall be distributed among the holders of the then outstanding Series A Preferred pro rata according to the number of outstanding shares of Series A Preferred held by each holder thereof.

3.2 Remaining Assets. If there are any Available Funds and Assets remaining after the payment or distribution (or the setting aside for payment or distribution) to the holders of the Series A Preferred of their full preferential amounts described above in this Section 3, then all such remaining Available Funds and Assets shall be distributed among the holders of the then outstanding Common Stock pro rata according to the number of shares of Common Stock held by each holder thereof.

3.3 Deemed Liquidation Events. Each of the following transactions shall be deemed to be a liquidation, dissolution or winding up of the Corporation as those terms are used in this Section 3: (a) any reorganization by way of share exchange, consolidation or merger, in one transaction or series of related transactions (each, a "combination transaction"), in which the Corporation is a constituent corporation or is a party with another entity if, as a result of such combination transaction, the voting securities of the Corporation that are outstanding immediately prior to the consummation of such combination transaction (other than any such securities that are held by an "Acquiring Shareholder", as defined below) do not represent, or are not converted into, securities of the surviving entity of such combination transaction (or such surviving entity's parent entity if the surviving entity is owned by the parent entity) that, immediately after the consummation of such combination transaction, together possess at least a majority of the total voting power of all securities of such surviving entity (or its parent entity, if applicable) that are outstanding immediately after the consummation of such combination transaction, including securities of such surviving entity (or its parent entity, if applicable) that are held by the Acquiring Shareholder; or (b) a sale of all or substantially all of the assets of the Corporation, that is followed by the distribution of the proceeds to the Company's shareholders. For purposes of this Section 3.4, an "Acquiring Shareholder" means a shareholder or shareholders of the Corporation that (i) merges or combines with the Corporation in such combination transaction or (ii) owns or controls a majority of the voting power of another entity that merges or combines with the Corporation in such combination transaction.

MedFire Innovations Inc.

3

Amended and Restated Articles of Incorporation

A0835033

# 4. REDEMPTION RIGHTS.

# 4.1 Redemption by Company.

(a) Subject to any liquidation preference rights which may have been previously invoked under Section 3 hereof, to the extent that any outstanding shares of Series A Preferred have not been previously redeemed at any time on or prior to January 1, 2030 (the "Company Redemption Start Date"), the Corporation may, at the option of the Board, redeem in whole or in part at any time on or after the Company Redemption Start Date, shares of Series A Preferred held by all or any number of selected holders of Series A Preferred, as such holders may be selected by the Board in its sole discretion, in cash at the Redemption Price specified in subsection 4.3 below, subject to the legal availability of funds therefor; and provided that immediately following any such redemption, the Corporation shall have outstanding a class of common shares that is not subject to redemption.

(b) Company Redemption Notice. At least sixty (60) days prior to the date upon which the Corporation intends to effect a redemption pursuant to section 4.1 above (such date, a "Company Redemption Date"), written notice shall be mailed by the Corporation, postage prepaid, to each holder of Series A Preferred to be redeemed (the "Redeemed Holders"), at the address last shown on the records of the Corporation for such Redeemed Holder or given by such holder to the Corporation for the purpose of notice or, if no such address appears or is given, at the place where the principal executive office of the Corporation is located, notifying such holder of the redemption to be effected, specifying the subsection hereof under which such redemption is being effected, the Company Redemption Date, the applicable Redemption Price, the number of such holder's shares of Series A Preferred to be redeemed, the place at which payment may be obtained and calling upon such holder to surrender to the Corporation, in the manner and at the place designated, the certificate or certificates representing the shares to be redeemed (the "Company Redemption Notice").

# 4.2 Redemption by Holder.

(a) Request for Redemption. Subject to the terms and conditions of this Section 4 and subject to any liquidation preference rights which may have been previously invoked under Section 3 hereof, to the extent that all of the outstanding shares of Series A Preferred held by a given holder of such Series A Preferred (each, a "Series A Holder") have not been redeemed prior to January 1, 2027 (the "Holder Redemption Start Date"), the Corporation shall, upon receiving a written request at any time after the Holder Redemption Start Date, signed by such Series A Holder (the "Holder Redemption Notice"), redeem, on the date that is sixty (60) days following its receipt of such Holder Redemption Notice from such Series A Holder (such date, a "Holder Redemption Date"), the full number of shares of Series A Preferred then held by such Series A Holder on the date the Corporation receives the Holder Redemption Notice from such Series A Holder; provided that immediately following any such redemption, the Corporation shall have outstanding a class of common shares that is not subject to redemption. The Series A Preferred held by such Series A Holder shall be redeemed in

MedFire Innovations Inc.

4

Amended and Restated Articles of Incorporation

A0835033

cash at the Redemption Price specified in Section 4.3 below and shall be paid from any source of funds legally available therefor, when and as such funds are legally available, until all outstanding shares of Series A Preferred to be redeemed have been redeemed as provided in Section 4 or the Redemption Request has been withdrawn or terminated as provided below.

(b) Withdrawal or Termination of Request. A Holder Redemption Notice may be withdrawn or terminated upon the request of the Series A Holder who originally submitted such Holder Redemption Notice, provided that none of the Series A Preferred shares held by such Series A Holder have been redeemed pursuant to such Holder Redemption Notice. After any such withdrawn or terminated Holder Redemption Notice, the shares of Series A Preferred held by such Series A Holder shall again be subject to redemption pursuant to this Section 4.

4.3 Redemption Price. The redemption price for each share of Series A Preferred Stock shall be an amount in cash equal to the Original Issue Price for the Series A Preferred Stock (as adjusted for any future stock dividends, combinations, splits, recapitalizations, and the like with respect to the shares) plus the amount of all accrued and unpaid dividends thereon (the "Redemption Price").

### 4.4 Redemption Default Event

(a) Insufficient Legally Available Funds. If upon any Company Redemption Date or Holder Redemption Date (each a "Redemption Date") scheduled under this Section 4 for the redemption of Series A Preferred, the funds and assets of the Corporation legally available to redeem such stock are insufficient to redeem all shares of Series A Preferred then scheduled to be redeemed, the Company may elect to pay the Redemption Price in the form of a promissory note (a "Redemption Note") for such amount, bearing interest at the rate of 5%, providing for fully amortized payments over a period of not more than two years, and containing other commercially reasonable terms as determined in the Company's discretion. In the event Company does not elect to pay the Redemption Price in the form of a Redemption Note, then any such unredeemed shares shall be carried forward and shall be redeemed (together with any other shares of Series A Preferred then scheduled to be redeemed) at the next such scheduled Redemption Date to the full extent of legally available funds of the Corporation at such time, and any such unredeemed shares shall continue to be so carried forward until redeemed. Shares of Series A Preferred that are subject to redemption hereunder but have not been redeemed due to insufficient legally available funds and assets of the Corporation shall continue to be outstanding and entitled to all dividend, liquidation and other rights, preferences, privileges and restrictions of the Series A Preferred respectively until such shares have been redeemed.

(b) Redemption Failure. Any failure on the part of the Corporation to pay in cash or with a Redemption Note the full amount of accrued and unpaid dividends due to any holder of Series A Preferred on any Redemption Date for any reason shall constitute a "Redemption Failure." In addition, any failure on the part of the Corporation to pay in cash the full amount of accrued and unpaid dividends due to any

MedFire Innovations Inc.

5

Amended and Restated Articles of Incorporation

A0835033

holder of Series A Preferred, pursuant to Section 3 above (pertaining to liquidation rights), shall also constitute a Redemption Failure. If a Redemption Failure exists, for whatever reason, for a cumulative time of at least eight quarters (whether or not such quarters are consecutive in time), then, upon the end of the eighth quarter of such Redemption Failure, the Corporation shall be deemed to have a "Redemption Default Event". Upon such Redemption Default Event, the voting requirements set forth in Section 5.2 of this Article shall be in effect, and shall remain in effect as set forth in Section 5.2.

4.5 Surrender of Certificates. On or before each designated Redemption Date, each holder of Series A Preferred to be redeemed shall surrender the certificate(s) representing such shares of Series A Preferred to be redeemed to the Corporation, in the manner and at the place designated in the Company Redemption Notice, if any, or at the place where the principal executive office of the Corporation is located, and thereupon the redemption price for such shares shall be payable to the order of the holder whose name appears on such certificate(s) as the owner thereof, and each surrendered certificate shall be cancelled and retired. If less than all of the shares represented by such certificate are redeemed, then the Corporation shall promptly issue a new certificate representing the unredeemed shares.

4.6 Effect of Redemption. If the Company Redemption Notice and/or the Holder Redemption Notice (each a "Redemption Notice") shall have been duly given, and if the Redemption Price is either paid or made available for payment through the deposit arrangements specified in subsection 4.7 below, then notwithstanding that the certificates evidencing any of the shares of Series A Preferred so called for redemption shall not have been surrendered, all dividends with respect to such shares shall cease to accrue after such Redemption Date, such shares shall not thereafter be transferred on the Corporation's books and the rights of all of the holders of such shares with respect to such shares shall terminate after such Redemption Date, except only the right of the holders to receive the redemption price without interest upon surrender of their certificate(s) therefor.

4.7 Deposit of Redemption Price. On or prior to the Redemption Date, the Corporation may, at its option, deposit with a bank or trust company in the State of California having a capital and surplus of at least Fifty Million Dollars ($50,000,000), as a trust fund, a sum equal to the aggregate Redemption Price for all shares of Series A Preferred called for redemption and not yet redeemed, with irrevocable instructions and authority to the bank or trust company to pay, on or after the Redemption Date, the Redemption Price to the respective holders upon the surrender of their share certificates. From and after the Redemption Date, the shares so called for redemption shall be redeemed. The deposit shall constitute full payment of the shares to their holders, and from and after the Redemption Date, the shares shall be deemed to be no longer outstanding, all dividends with respect to such shares shall cease to accrue and the holders thereof shall cease to be shareholders with respect to such shares and shall have no rights with respect thereto except the right to receive from the bank or trust company payment of the Redemption Price of the shares, without interest, upon surrender of their certificates therefor. Any funds so deposited and unclaimed at the end of one (1) year

MedFire Innovations Inc.

6

Amended and Restated Articles of Incorporation

A0835033

from the Redemption Date shall be released or repaid to the Corporation, after which time the holders of shares called for redemption who have not claimed such funds shall be entitled to receive payment of the Redemption Price only from the Corporation.

# 5. VOTING RIGHTS.

5.1 Non-Voting Stock. The Series A Preferred is NON-voting, except as provided by law and except as provided below.

5.2 Board. The holders of record of the outstanding shares of Common Stock of the Corporation shall be entitled to elect all directors of the Corporation, provided, however, that upon a Redemption Default Event, so long as such Redemption Default Event is continuing, the holders of record of at least a majority of the outstanding shares of Series A Preferred, voting separately as a separate class, shall have the right, but not the obligation, to elect a majority of the directors of the Corporation ("Series A Election Right"). The Series A Election Right shall remain in place until such time as the payment of all arrears of dividend due to holders of Series A Preferred have been paid in full.

6. CONVERSION. At any time on or after January 1, 2027 (the "Conversion Start Date"), any holder of outstanding shares of Series A Preferred Stock may elect to convert such shares into an equal number of fully paid and nonassessable shares of Common Stock, subject to the availability of authorized but unissued shares of Common Stock. All shares of Series A Preferred Stock so converted will, as of the effective date of such conversion as declared by the Board, be no longer deemed to be outstanding, and all rights with respect to such shares shall immediately cease and terminate as of such effective date, except only the right of the holders thereof to receive shares of Class A Common Stock in exchange therefor and to receive payment of any dividends accrued but unpaid thereon as of the effective date of such conversion. In the event that, prior to a conversion, the Common Stock is subject to a stock split, stock dividend or other similar transaction involving the issuance of Common Stock without consideration paid therefor, and the Series A Preferred Stock is not affected on an equal basis, then the shares of Common Stock into which the Series A Preferred Stock may be converted, as provided in this section, will be adjusted accordingly. No fractional shares of Common Stock shall be issued upon conversion of the Series A Preferred Stock. In lieu of any fractional shares to which the holder would otherwise be entitled, the Corporation shall pay cash equal to such fraction multiplied by the fair market value of a share of Common Stock as determined in good faith by the Board.

# ARTICLE V:

# LIMITATION OF LIABILITY

The liability of the directors of the corporation for monetary damages shall be eliminated to the fullest extent permissible under California law. Unless applicable law otherwise provides, any amendment, repeal or modification of this Article V shall not adversely affect any right or protection of a director under this Article V that existed at or prior to the time of such amendment, repeal or modification.

MedFire Innovations Inc.

7

Amended and Restated Articles of Incorporation

A0835033

# ARTICLE VI:

# INDEMNIFICATION

1. The Corporation is authorized to provide indemnification of agents (as defined in Section 317 of the General Corporation Law of California) for breach of duty to the Corporation and its shareholders through bylaw provisions or through agreements with agents, or both, in excess of the indemnification otherwise permitted by Section 317 of the General Corporation Law of California, subject to the limits on such excess indemnification set forth in Section 204 of the General Corporation Law of California. If, after the effective date of this Article, California law is amended in a manner which permits a corporation to limit the monetary or other liability of its directors or to authorize indemnification of, or advancement of such defense expenses to, its directors or other persons, in any such case to a greater extent than is permitted on such effective date, the references in this Article to "California law" shall to that extent be deemed to refer to California law as so amended.

2. Any repeal or modification of this Article shall only be prospective and shall not affect the rights under this Article in effect at the time of the alleged occurrence of any action or omission to act giving rise to liability.

C. The foregoing Amended and Restated Articles of Incorporation has been duly approved by the board of directors.
D. The foregoing Amended and Restated Articles of Incorporation has been duly approved by the required vote of shareholders in accordance with Section 902, California Corporations Code. The total number of outstanding shares of the corporation is 783,000 shares of Common Stock; no shares of Preferred Stock are outstanding. The number of shares voting in favor of the amendment equaled or exceeded the vote required. The percentage vote required was more than \(50\%\) of the outstanding shares.

I further declare under penalty of perjury under the laws of the State of California that the matters set forth in this certificate are true and correct of our own knowledge.

![img-0.jpeg](img-0.jpeg)

Date: October 21, 2019

MedFire Innovations Inc.

8

Amended and Restated Articles of Incorporation

**Attachment 10:** `imedoffering.pdf`

# **MedFire Innovations, Inc.**
**(Offering Script)**

MedFire Innovations is taking a NEW approach to improving the lives of patients and providers by developing and launching products that change health and community care.

For over five years, we have combined deep industry knowledge with best-in-class practices, considering three key factors:

-Patient fears, concerns and opportunities for empowerment
-What healthcare workers need to perform procedures successfully, with an emphasis on ease, comfort and protection; and
-Everyday challenges faced by healthcare and first responders.

Our products deliver simpler solutions to large and pressing market problems.

Some of our successes to date include:

-A patented product to provide a protective potential barrier to pathogens between a person and a surface such as a hospital mattress

-A device developed to assist in the application of a novel biomaterial formulation used in the treatment of skin lesions.

-A passive entry tool first-responders can use to enter locked areas without causing damage.

-A device for patients with dependencies or disabilities that allows a caregiver to obtain a urine specimen without the embarrassment of or discomfort of a catheter.

We are also in the final phases of developing a device that will change, on a global scale, how women are tested for life-threatening cervical cancer. Unlike current tests, it will allow a patient to obtain their own sample for analysis, easily and discretely, in their own home.

This devices MedFire develops aren't just helpful or interesting - they are necessary gamechangers.

The healthcare market is growing and the opportunities to improve gaps in how care is delivered are specific and powerful.

Join us, and support product innovation that will transform the healthcare landscape here and around the world.

Invest with impact. Invest in MedFire, and let's make a difference together.

**Attachment 11:** `jmedjobexpo.pdf`

# MedFire Jobs & Expo

The MedFire Jobs and Expo is a platform specifically serving the needs of job seekers and companies in the Healthcare, Science, Veterinary and Public Safety fields.

We offer a thorough database for companies and organizations to use in recruiting top-tier job candidates in search of great careers. Where job candidates can go straight to the organization they want to work for.

But MedFire offers much more than recruitment:

MedFire Expo is an EDUCATION HUB, providing training for those entering a new challenging field AND continuing education for those seeking to refine skills.

MedFire Expo is a RESOURCE LIBRARY, with industry-related stories, blogs, podcasts, photo journals and more.

MedFire Expo is a CONNECTOR, for job recruitment as well as peer-to-peer connection and collaboration, sharing news, information and research.

MedFire Jobs & Expo is a LAUNCHPAD - a place for organizations to market, advertise and demonstrate their products and services directly to their preferred audiences.

MedFire Jobs & Expo is GLOBAL - offering information, partners and opportunities in the United States and also throughout the world.

Use MedFire Jobs and Expo to find and connect with others who share your dedication to protecting America.

Join the growing MedFire community today.

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM C

### UNDER THE SECURITIES ACT OF 1933

### Issuer Information

**Name of Issuer:** MedFire Innovations Inc.

**Legal Status:** Corporation

**Jurisdiction of Incorporation/Organization:** CA

**Date of Organization:** 06-22-2016

**Physical Address:** 2425 CAMINO DEL RIO SOUTH, STE. 125, SAN DIEGO, CA, 92108

**Issuer Website:** www.medfire.com

**Is there a Co-Issuer?:** No

**Intermediary Name:** MiTec, PBC

**Intermediary CIK:** 0001690300

**Intermediary File Number:** 007-00133

**Intermediary CRD Number:** 292759

### Offering Information

**Compensation to Intermediary:** 6% of proceeds distributed to the issuer plus third-party background checks and escrow fees.

**Financial Interest in Issuer:** None

**Type of Security Offered:** Preferred Stock

**Number of Securities Offered:** 5000

**Price per Security:** $10.00

**Method for Determining Price:** Face Value

**Target Offering Amount:** $50,000.00

**Oversubscription Accepted:** Yes

**Oversubscription Allocation Type:** First-come, first-served basis

**Maximum Offering Amount:** $1,000,000.00

**Deadline to Reach Target Amount:** 04-30-2023

### Annual Report Disclosure Requirements

**Current Number of Employees:** 2.00

**Total Assets (Most Recent Fiscal Year):** $99,984.00

**Total Assets (Prior Fiscal Year):** $96,275.00

**Cash & Cash Equivalents (Most Recent Fiscal Year):** $27,408.00

**Cash & Cash Equivalents (Prior Fiscal Year):** $32,059.00

**Accounts Receivable (Most Recent Fiscal Year):** $0.00

**Accounts Receivable (Prior Fiscal Year):** $0.00

**Short-Term Debt (Most Recent Fiscal Year):** $32,998.00

**Short-Term Debt (Prior Fiscal Year):** $31,443.00

**Long-Term Debt (Most Recent Fiscal Year):** $101,762.00

**Long-Term Debt (Prior Fiscal Year):** $94,289.00

**Revenues/Sales (Most Recent Fiscal Year):** $21,762.00

**Revenues/Sales (Prior Fiscal Year):** $187,068.00

**Cost of Goods Sold (Most Recent Fiscal Year):** $17,573.00

**Cost of Goods Sold (Prior Fiscal Year):** $102,687.00

**Taxes Paid (Most Recent Fiscal Year):** $2,268.00

**Taxes Paid (Prior Fiscal Year):** $800.00

**Net Income (Most Recent Fiscal Year):** $0.00

**Net Income (Prior Fiscal Year):** $0.00

**Jurisdictions Offered:**

ALABAMA, ALASKA, ARIZONA, ARKANSAS, CALIFORNIA, COLORADO, CONNECTICUT, DELAWARE, DISTRICT OF COLUMBIA, FLORIDA, GEORGIA, HAWAII, IDAHO, ILLINOIS, INDIANA, IOWA, KANSAS, KENTUCKY, LOUISIANA, MAINE, MARYLAND, MASSACHUSETTS, MICHIGAN, MINNESOTA, MISSISSIPPI, MISSOURI, MONTANA, NEBRASKA, NEVADA, NEW HAMPSHIRE, NEW JERSEY, NEW MEXICO, NEW YORK, NORTH CAROLINA, NORTH DAKOTA, OHIO, OKLAHOMA, OREGON, PENNSYLVANIA, PR, RHODE ISLAND, SOUTH CAROLINA, SOUTH DAKOTA, TENNESSEE, TEXAS, UTAH, VERMONT, VIRGINIA, WASHINGTON, WEST VIRGINIA, WISCONSIN, WYOMING, ALBERTA, BRITISH COLUMBIA, MANITOBA, NEW BRUNSWICK, NEWFOUNDLAND, NOVA SCOTIA, ONTARIO, PRINCE EDWARD ISLAND, QUEBEC, SASKATCHEWAN, YUKON TERRITORY, ISRAEL

### Signatures

**Issuer:** MedFire Innovations Inc.

**Signature:** DawnMarin Dell

**Title:** Attorney

---

**Signature:** DawnMarin Dell

**Title:** Attorney

**Date:** 01-27-2023